<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS Comput Biol</journal-id><journal-id journal-id-type="iso-abbrev">PLoS Comput. Biol</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">ploscomp</journal-id><journal-title-group><journal-title>PLoS Computational Biology</journal-title></journal-title-group><issn pub-type="ppub">1553-734X</issn><issn pub-type="epub">1553-7358</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6336352</article-id><article-id pub-id-type="pmid">30615612</article-id><article-id pub-id-type="doi">10.1371/journal.pcbi.1006664</article-id><article-id pub-id-type="publisher-id">PCOMPBIOL-D-18-01501</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cell Processes</subject><subj-group><subject>Cell Cycle and Cell Division</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Blood Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>Granulocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>Granulocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>Granulocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>Granulocytes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Bone Marrow Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Stem Cells</subject><subj-group><subject>Hematopoietic Stem Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Mutation</subject><subj-group><subject>Point Mutation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Physiological Processes</subject><subj-group><subject>Hematopoiesis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Physiological Processes</subject><subj-group><subject>Hematopoiesis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Women's Health</subject><subj-group><subject>Maternal Health</subject><subj-group><subject>Birth</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Women's Health</subject><subj-group><subject>Obstetrics and Gynecology</subject><subj-group><subject>Birth</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Carcinogenesis</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Mutation, drift and selection in single-driver hematologic malignancy: Example of secondary myelodysplastic syndrome following treatment of inherited neutropenia</article-title><alt-title alt-title-type="running-head">Evolutionary model of MDS</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wojdyla</surname><given-names>Tomasz</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-9140-9765</contrib-id><name><surname>Mehta</surname><given-names>Hrishikesh</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Glaubach</surname><given-names>Taly</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Methodology</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bertolusso</surname><given-names>Roberto</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Software</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Iwanaszko</surname><given-names>Marta</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff005"><sup>5</sup></xref><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Braun</surname><given-names>Rosemary</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff006"><sup>6</sup></xref><xref ref-type="aff" rid="aff007"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Corey</surname><given-names>Seth J.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref><xref ref-type="aff" rid="aff003"><sup>3</sup></xref><xref ref-type="aff" rid="aff008"><sup>8</sup></xref><xref ref-type="author-notes" rid="econtrib001"><sup>&#x02021;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kimmel</surname><given-names>Marek</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff005"><sup>5</sup></xref><xref ref-type="aff" rid="aff009"><sup>9</sup></xref><xref ref-type="author-notes" rid="econtrib001"><sup>&#x02021;</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Systems Engineering Group, Silesian University of Technology, Gliwice, Poland</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Pediatrics, Cleveland Clinic, Cleveland, OH, United States of America</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Cancer Biology, Cleveland Clinic, Cleveland, OH, United States of America</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Clinical Pediatrics, Division of Hospital Medicine, Stony Brook Children's Hospital, Stony Brook, New York</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Department of Statistics, Rice University, Houston, TX, United States of America</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>Department of Preventive Medicine&#x02013;Division of Biostatistics, Northwestern University, Chicago, IL United States of America</addr-line></aff><aff id="aff007"><label>7</label>
<addr-line>Department of Engineering Sciences and Applied Mathematics, Northwestern University, Evanston, IL United States of America</addr-line></aff><aff id="aff008"><label>8</label>
<addr-line>Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, United States of America</addr-line></aff><aff id="aff009"><label>9</label>
<addr-line>Department of Bioengineering, Rice University, Houston, TX, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Gallo</surname><given-names>James</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>University at Buffalo - The State University of New York, UNITED STATES</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p>The authors have declared that no competing interests exist.</p></fn><fn fn-type="other" id="econtrib001"><p><sup>&#x02021;</sup> These authors are joint senior authors on this work.</p></fn><corresp id="cor001">* E-mail: <email>kimmel@stat.rice.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>7</day><month>1</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2019</year></pub-date><volume>15</volume><issue>1</issue><elocation-id>e1006664</elocation-id><history><date date-type="received"><day>29</day><month>8</month><year>2018</year></date><date date-type="accepted"><day>19</day><month>11</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2019 Wojdyla et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Wojdyla et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pcbi.1006664.pdf"/><abstract><p>Cancer development is driven by series of events involving mutations, which may become fixed in a tumor via genetic drift and selection. This process usually includes a limited number of driver (advantageous) mutations and a greater number of passenger (neutral or mildly deleterious) mutations. We focus on a real-world leukemia model evolving on the background of a germline mutation. Severe congenital neutropenia (SCN) evolves to secondary myelodysplastic syndrome (sMDS) and/or secondary acute myeloid leukemia (sAML) in 30&#x02013;40%. The majority of SCN cases are due to a germline <italic>ELANE</italic> mutation. Acquired mutations in <italic>CSF3R</italic> occur in &#x0003e;70% sMDS/sAML associated with SCN. Hypotheses underlying our model are: an <italic>ELANE</italic> mutation causes SCN; <italic>CSF3R</italic> mutations occur spontaneously at a low rate; in fetal life, hematopoietic stem and progenitor cells expands quickly, resulting in a high probability of several tens to several hundreds of cells with <italic>CSF3R</italic> truncation mutations; therapeutic granulocyte colony-stimulating factor (G-CSF) administration early in life exerts a strong selective pressure, providing mutants with a growth advantage. Applying population genetics theory, we propose a novel two-phase model of disease development from SCN to sMDS. In Phase 1, hematopoietic tissues expand and produce tens to hundreds of stem cells with the <italic>CSF3R</italic> truncation mutation. Phase 2 occurs postnatally through adult stages with bone marrow production of granulocyte precursors and positive selection of mutants due to chronic G-CSF therapy to reverse the severe neutropenia. We predict the existence of the pool of cells with the mutated truncated receptor <italic>before</italic> G-CSF treatment begins. The model does not require increase in mutation rate under G-CSF treatment and agrees with age distribution of sMDS onset and clinical sequencing data.</p></abstract><abstract abstract-type="summary"><title>Author summary</title><p>Cancer develops by multistep acquisition of mutations in a progenitor cell and its daughter cells. Severe congenital neutropenia (SCN) manifests itself through an inability to produce enough granulocytes to prevent infections. SCN commonly results from a germline <italic>ELANE</italic> mutation. Large doses of the blood growth factor granulocyte colony-stimulating factor (G-CSF) rescue granulocyte production. However, SCN frequently transforms to a myeloid malignancy, commonly associated with a somatic mutation in <italic>CSF3R</italic>, the gene encoding the G-CSF Receptor. We built a mathematical model of evolution for <italic>CSF3R</italic> mutation starting with bone marrow expansion at the fetal development stage and continuing with postnatal competition between normal and malignant bone marrow cells. We employ tools of probability theory such as multitype branching processes and Moran models modified to account for expansion of hematopoiesis during human development. With realistic coefficients, we obtain agreement with the age range at which malignancy arises in patients. In addition, our model predicts the existence of a pool of cells with mutated <italic>CSF3R</italic> before G-CSF treatment begins. Our findings may be clinically applied to intervene more effectively and selectively in SCN patients.</p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01HL128173</award-id><principal-award-recipient><name><surname>Corey</surname><given-names>Seth J.</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100004281</institution-id><institution>Narodowe Centrum Nauki</institution></institution-wrap></funding-source><award-id>DEC-2012/04/A/ST7/00353</award-id><principal-award-recipient><name><surname>Kimmel</surname><given-names>Marek</given-names></name></principal-award-recipient></award-group><award-group id="award003"><funding-source><institution>American Society of Hematology</institution></funding-source><award-id>RO1CA108992,</award-id><principal-award-recipient><name><surname>Corey</surname><given-names>Seth J.</given-names></name></principal-award-recipient></award-group><funding-statement>TW and MK were supported by the grant DEC-2012/04/A/ST7/00353 from the National Science Center (Poland). MK, MI, RB, HM, and SJC were supported by NIH R01HL128173. HM was supported by a Leukemia Research Foundation award. TG was supported by an MDS International Foundation Young Investigator Award. SJC was supported by grants from the NIH RO1CA108992, American Society for Hematology Bridge Award, Leukemia and Lymphoma Translational Award, and the Department of Defense Bone Marrow Failure IDEA grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="6"/><table-count count="2"/><page-count count="22"/></counts><custom-meta-group><custom-meta><meta-name>PLOS Publication Stage</meta-name><meta-value>vor-update-to-uncorrected-proof</meta-value></custom-meta><custom-meta><meta-name>Publication Update</meta-name><meta-value>2019-01-17</meta-value></custom-meta><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the manuscript and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the manuscript and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Cancer development is driven by series of mutational events, which may become fixed in a hematologic or non-hematologic tumor via genetic drift. This process usually includes a limited number of driver (advantageous) mutations, and a greater number of passenger (neutral or mildly deleterious) mutations. Driver mutations for several hundred different cancers have been identified by sequencing and functional assays. The relationship between driver and passenger mutations has been investigated using mathematical models representing carcinogenesis in terms of a &#x0201c;tug-of war&#x0201d; between the former and the latter [<xref rid="pcbi.1006664.ref001" ref-type="bibr">1</xref>, <xref rid="pcbi.1006664.ref002" ref-type="bibr">2</xref>]. Another related problem is whether carcinogenesis is driven by acquisition of single point mutations or by saltatory changes amounting to major genome rearrangement events [<xref rid="pcbi.1006664.ref003" ref-type="bibr">3</xref>, <xref rid="pcbi.1006664.ref004" ref-type="bibr">4</xref>]. Mathematical modeling of interactions among multiple drivers has been described by Nowak and Durrett and their colleagues [<xref rid="pcbi.1006664.ref005" ref-type="bibr">5</xref>&#x02013;<xref rid="pcbi.1006664.ref007" ref-type="bibr">7</xref>]. These frequently involve branching processes and related mathematical models [<xref rid="pcbi.1006664.ref008" ref-type="bibr">8</xref>]. Among stochastic models in hematology, an example is [<xref rid="pcbi.1006664.ref009" ref-type="bibr">9</xref>]. Hematopoiesis provide the best-characterized system for cell fate decision-making in both health and disease [<xref rid="pcbi.1006664.ref010" ref-type="bibr">10</xref>], as well as connections between stimuli such as inflammation and cancer [<xref rid="pcbi.1006664.ref011" ref-type="bibr">11</xref>].</p><p>Here, we model a disease evolving on the background of a germline mutation. The acquired driver mutation recurs during tissue expansion phase in fetal life and becomes selectively advantageous in early childhood, leading to development of malignancy. As a prominent example of such disease, we model the important hematologic disorder Severe Congenital Neutropenia (SCN), a monogenic inherited disorder, that acquires new mutations and evolves to secondary myelodysplastic syndrome (sMDS) or secondary acute myeloid leukemia (sAML). This model is similar to the &#x0201c;fish&#x0201d; graph of Tomasetti and Vogelstein [<xref rid="pcbi.1006664.ref012" ref-type="bibr">12</xref>]; however the latter is more comprehensive and involves multiple driver case. Here, we use tools of population genetics and population dynamics to model progression from SCN to sMDS and dissect the contributions of mutation, drift and selection at different stages of an individual&#x02019;s life. More specifically, we consider:</p><list list-type="order"><list-item><p>In an individual primed by an inherited genotype, the driver mutation occurs recurrently in the embryonic expansion stage, although these mutations do not necessarily confer selective advantage.</p></list-item><list-item><p>At birth, due to environmental and behavioral factors or treatment, the driver mutation acquires a selective advantage in a tissue or organ, while the driver mutation may or may not recur as frequently any more.</p></list-item><list-item><p>The mutant driver variant increases in frequency due to selection, and eventually it dominates the stem cells of the tissue or the organ, contributing to development of disease.</p></list-item></list><p>Accordingly, SCN is most commonly due to germline mutations in <italic>ELANE</italic>, which encodes the neutrophil elastase [<xref rid="pcbi.1006664.ref013" ref-type="bibr">13</xref>]. SCN is characterized by the near absence of circulating neutrophils, which renders the child, typically an infant, susceptible to recurrent life-threatening infections. The introduction in the 1990s of recombinant granulocyte colony-stimulating factor (G-CSF) to increase circulating neutrophils, markedly improved survival and quality of life for SCN patients [<xref rid="pcbi.1006664.ref014" ref-type="bibr">14</xref>].</p><p>SCN often transforms into sMDS or sAML [<xref rid="pcbi.1006664.ref015" ref-type="bibr">15</xref>, <xref rid="pcbi.1006664.ref016" ref-type="bibr">16</xref>]. Clinical studies have demonstrated a strong association between exposure to G-CSF and sMDS/AML [<xref rid="pcbi.1006664.ref017" ref-type="bibr">17</xref>&#x02013;<xref rid="pcbi.1006664.ref021" ref-type="bibr">21</xref>]. Mutations in the distal domain of the Granulocyte Colony-Stimulating Factor Receptor (<italic>CSF3R</italic>) have been isolated from almost all SCN patients who developed sMDS/AML [<xref rid="pcbi.1006664.ref022" ref-type="bibr">22</xref>, <xref rid="pcbi.1006664.ref023" ref-type="bibr">23</xref>]. Clonal evolution over approximately 20 years was documented using next generation sequencing and quantification of <italic>CSF3R</italic> allele frequency variation in an SCN patient who developed sMDS/sAML [<xref rid="pcbi.1006664.ref024" ref-type="bibr">24</xref>]. Strikingly, out of four different mutations in <italic>CSF3R</italic>, one persisted into the leukemic clone but the other three were lost, supporting the assumption of different selective values in the presence of G-CSF that underlies our model. As clonal evolution is a central feature in cancer [<xref rid="pcbi.1006664.ref025" ref-type="bibr">25</xref>&#x02013;<xref rid="pcbi.1006664.ref028" ref-type="bibr">28</xref>] and next generation sequencing has revealed complex genomic landscapes, SCN may provide a simpler real-world example to study cancer development.</p><p>Two opposing paradigms have been proposed for cell fate decision making in blood cells: stochastic hematopoiesis (based on variability observed in cultured bone marrow cells as first suggested by McCulloch and Till [<xref rid="pcbi.1006664.ref029" ref-type="bibr">29</xref>]) and deterministic, or instructive, hematopoiesis (growth factor-driven production of specific blood cell types) [<xref rid="pcbi.1006664.ref030" ref-type="bibr">30</xref>, <xref rid="pcbi.1006664.ref031" ref-type="bibr">31</xref>]. In spite of substantial experimental findings, particularly recent single-cell measurements [<xref rid="pcbi.1006664.ref032" ref-type="bibr">32</xref>], the two opposing theories await a grand synthesis. Disease-accompanying dynamics have been variously modeled over the years as deterministic or stochastic[<xref rid="pcbi.1006664.ref010" ref-type="bibr">10</xref>]. SCN may also provide a simpler real-world example to study cell fate determination.</p><p>Little is known about the molecular mechanism(s) by which SCN leads to myeloid malignancy and how important are the truncating mutations such as <italic>CSF3R D715</italic> in this process. Notwithstanding the exact molecular mechanism by which the <italic>CSF3R</italic> truncation mutants lead to sMDS/AML, two pivotal questions concerning the population dynamics and population genetics of the mutant clones are: (i) whether the <italic>CSF3R</italic> truncation mutants are present before application of G-CSF, and (ii) whether G-CSF administration increases mutation rate in hematopoietic stem cells with <italic>ELANE</italic> mutation. If the answer to the first question is affirmative, then the presence of a small subpopulation of <italic>CSF3R</italic> truncation mutants among infants with SCN might be of prognostic value and a preventive therapy might be sought. Concerning the second question, determination whether G-CSF is mutagenic or provides a selective pressure may influence the degree G-CSF therapy is conducted, e.g. should it be more or less aggressive.</p><p>To provide insight into the course of this disease and its clinical management, we propose a novel model of the emergence and fixation of <italic>CSF3R</italic> truncating mutations, which also follows the paradigm outlined earlier on. We note that the most common of these mutations associated with transition to sMDS is the <italic>CSF3R D715</italic>. However, at the resolution level of our model, we are not able to make more specific distinctions nor to consider coexistence or competition of more than one truncation mutant. The model assumes that the answer to question (i) is affirmative, but it is negative to question (ii). The model&#x02019;s hypotheses are:</p><list list-type="order"><list-item><p>An inherited mutation in <italic>ELANE</italic> causes SCN;</p></list-item><list-item><p><italic>ELANE</italic> mutations coexist with the non-mutated allele in an intracellular environment in which <italic>CSF3R</italic> truncating mutations occur spontaneously at a low rate;</p></list-item><list-item><p>During fetal life, the number of stem cells and committed cells expands quickly, which results in high probability of approximately <inline-formula id="pcbi.1006664.e001"><alternatives><graphic xlink:href="pcbi.1006664.e001.jpg" id="pcbi.1006664.e001g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M1"><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:math></alternatives></inline-formula>
<italic>CSF3R</italic> truncation mutant cells; these would be of no consequence had their number not expanded further;</p></list-item><list-item><p>Administration of pharmacologic G-CSF early in life exerts selective pressure, providing <italic>CSF3R</italic> mutants with selective advantage. This assumption is supported by experiments, in which growth differential of wild-type and truncation mutant depends on the G-CSF concentration (<bold><xref ref-type="fig" rid="pcbi.1006664.g001">Fig 1</xref></bold>).</p></list-item></list><fig id="pcbi.1006664.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1006664.g001</object-id><label>Fig 1</label><caption><p><bold>(A). Effect of CSF3R (wild type or D715) stimulation on cell cycle</bold>. Ba/F3 cells expressing either wild type (Type I, blue) or mutant (D715, red) CSF3R were stimulated with two different doses of G-CSF (50 ng/ml and 100 ng/ml) and were analyzed using flow cytometry to determine the effect of G-CSF dose on receptor subtype activation on cell cycle progression. The cells were treated as detailed in the <bold>Methods</bold>. Flow cytometry data for each time point were analyzed using FlowJo employing the built-in cell cycle module. The data are represented as percentage of G1/G0 cells obtained from the FlowJo analysis plotted against time. Following an initial transient, from the 1 hr time point the G1/G0 percentage differences between cells with the Type I and D715 receptors have been on the average equal to 6.05% for 100 ng of G-CSF and 4.28% for 50 ng of G-CSF, respectively.</p></caption><graphic xlink:href="pcbi.1006664.g001"/></fig><list list-type="order"><list-item><p>Onset of sMDS is equivalent with replacement of normal hematopoietic bone marrow by mutant hematopoietic stem cells, their progeny, and release of factors that suppress normal hematopoiesis. At the level of resolution of our model, we are not able to make more specific distinctions.</p></list-item></list><p><bold>(B) Effect of CSF3R (wild type vs. D715) on cell proliferation</bold>. Ba/F3 cells expressing either wild type (Type I) or mutant (D715) <italic>CSF3R</italic> were treated with increasing doses of recombinant human G-CSF (ng/ml) and proliferation was measured by the MTT assay performed in triplicates in a 96 well plate. The data are raw absorbance values at 600 nm and represent the three replicates plotted against increasing dose of G-CSF, fitted using least squares by Hill-type curves (Type I, blue, D715 red). For details of experimental procedures see the <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold>. Fitting and statistical procedures are explained in the <bold>Methods</bold>.</p><p>We show that hypotheses 2 and 3 are needed, by first building a proof-of-principle simple Moran process (a stochastic model used in population genetics) with no expansion, which fits the data only if it is started by a cell population including <inline-formula id="pcbi.1006664.e002"><alternatives><graphic xlink:href="pcbi.1006664.e002.jpg" id="pcbi.1006664.e002g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M2"><mml:mo>&#x02053;</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:math></alternatives></inline-formula> cells expressing a <italic>CSF3R</italic> truncation mutation. Then we show that this number of <italic>CSF3R</italic> truncation mutant cells can be produced in the late fetal period expansion of hematopoiesis in bone marrow. Existence of the pool of <italic>CSF3R</italic> truncation mutant cells before exposure to G-CSF can be discovered only by deep targeted sequencing. Then we follow up with a full-fledged comprehensive model, which accounts for the important detail of time change of the size of the hematopoietic system, but which confirms the conclusions of the proof-of-principle model.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Methods</title><sec id="sec003"><title>Measuring the selective advantage of D 715 mutant cells</title><sec id="sec004"><title>Experiment</title><p>As shown in <bold><xref ref-type="fig" rid="pcbi.1006664.g001">Fig 1A</xref></bold>, the fraction of Ba/F3 cells expressing either wild type (Type I, blue) or mutant (D715, red) CSF3R that reside in the G1/G0 phase has been measured, employing flow cytometry. Technical details are found in the <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold>. Briefly, following release from the starvation cell cycle arrest, cells were stimulated with two different doses of G-CSF (50 ng/ml and 100 ng/ml) and were analyzed using flow cytometry to determine the effect of G-CSF dose on receptor subtype activation in terms of cell cycle progression. Flow cytometry data for each time point were analyzed using FlowJo software [<xref rid="pcbi.1006664.ref033" ref-type="bibr">33</xref>] employing the built-in cell cycle module. The data are represented as percentage of G1/G0 cells obtained from the FlowJo analysis plotted against time. After an initial transient, from the 1 hr time point the G1/G0 percentage differences between cells with the Type I and D715 receptors have been on the average equal to 6.05% for 100 ng of G-CSF and 4.28% for 50 ng of G-CSF, respectively. The data points are derived from flow cytometry, and because it measures thousands of cells, statistical fluctuations play a minor role and therefore the differences are statistically &#x0201c;highly significant&#x0201d;.</p><p>G1/G0 cell fraction as a measure of selective advantage of cycling cells. We employ a simple cell cycle model to relate the G1/G0 cell fraction to the cell growth rate and selective advantage. Mathematical foundations can be found for example in ref. [<xref rid="pcbi.1006664.ref034" ref-type="bibr">34</xref>, <xref rid="pcbi.1006664.ref035" ref-type="bibr">35</xref>]. Briefly, suppose that the interdivision time <inline-formula id="pcbi.1006664.e003"><alternatives><graphic xlink:href="pcbi.1006664.e003.jpg" id="pcbi.1006664.e003g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M3"><mml:mi>T</mml:mi></mml:math></alternatives></inline-formula> of cell in a population is constant and that the residence time <inline-formula id="pcbi.1006664.e004"><alternatives><graphic xlink:href="pcbi.1006664.e004.jpg" id="pcbi.1006664.e004g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M4"><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math></alternatives></inline-formula> in the G1/G0 is also constant (relaxing these assumptions is possible, as implicit from [<xref rid="pcbi.1006664.ref034" ref-type="bibr">34</xref>, <xref rid="pcbi.1006664.ref035" ref-type="bibr">35</xref>], but it does not affect the first-order approximation we need here). Let us also suppose that the efficiency of divisions <inline-formula id="pcbi.1006664.e005"><alternatives><graphic xlink:href="pcbi.1006664.e005.jpg" id="pcbi.1006664.e005g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M5"><mml:mi>&#x003b1;</mml:mi></mml:math></alternatives></inline-formula> (probability that a progeny cell enters the cell cycle) is constant. Under these hypotheses, the expected cell growth after initial transients becomes exponential with rate <inline-formula id="pcbi.1006664.e006"><alternatives><graphic xlink:href="pcbi.1006664.e006.jpg" id="pcbi.1006664.e006g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M6"><mml:mi>&#x003bb;</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mrow><mml:mi mathvariant="normal">ln</mml:mi></mml:mrow><mml:mo>&#x02061;</mml:mo><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mn>2</mml:mn><mml:mi>&#x003b1;</mml:mi></mml:mrow></mml:mfenced></mml:mrow></mml:mrow><mml:mo>/</mml:mo><mml:mi>T</mml:mi></mml:math></alternatives></inline-formula>, i.e. the cell count at time <inline-formula id="pcbi.1006664.e007"><alternatives><graphic xlink:href="pcbi.1006664.e007.jpg" id="pcbi.1006664.e007g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M7"><mml:mi>t</mml:mi></mml:math></alternatives></inline-formula> is equal to
<disp-formula id="pcbi.1006664.e008"><alternatives><graphic xlink:href="pcbi.1006664.e008.jpg" id="pcbi.1006664.e008g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M8"><mml:mrow><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>)</mml:mo></mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>&#x003bb;</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:math></alternatives></disp-formula></p><p>The fraction <inline-formula id="pcbi.1006664.e009"><alternatives><graphic xlink:href="pcbi.1006664.e009.jpg" id="pcbi.1006664.e009g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M9"><mml:mi>&#x003c6;</mml:mi></mml:math></alternatives></inline-formula> of cells in G1/G0, tends to the following value
<disp-formula id="pcbi.1006664.e010"><alternatives><graphic xlink:href="pcbi.1006664.e010.jpg" id="pcbi.1006664.e010g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M10"><mml:mrow><mml:mi>&#x003c6;</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mi>&#x003bb;</mml:mi><mml:msub><mml:mi>T</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mi>&#x003bb;</mml:mi><mml:mi>T</mml:mi></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:math></alternatives></disp-formula></p><p>This latter expression can be solved for the ratio <inline-formula id="pcbi.1006664.e011"><alternatives><graphic xlink:href="pcbi.1006664.e011.jpg" id="pcbi.1006664.e011g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M11"><mml:mi>&#x003c8;</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mi>T</mml:mi></mml:math></alternatives></inline-formula>
<disp-formula id="pcbi.1006664.e012"><alternatives><graphic xlink:href="pcbi.1006664.e012.jpg" id="pcbi.1006664.e012g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M12"><mml:mrow><mml:mi>&#x003c8;</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mtext>ln</mml:mtext><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mi>&#x003c6;</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>&#x003b1;</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mtext>ln</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mi>&#x003b1;</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:math></alternatives></disp-formula></p><p>Suppose now that we consider another (&#x0201c;asterisked&#x0201d;) population of cycling cells, which has respective parameters denoted with superscript <inline-formula id="pcbi.1006664.e013"><alternatives><graphic xlink:href="pcbi.1006664.e013.jpg" id="pcbi.1006664.e013g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M13"><mml:msup><mml:mrow><mml:mo>(</mml:mo></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msup><mml:mo>)</mml:mo><mml:mo>.</mml:mo></mml:math></alternatives></inline-formula>Let us also assume that the difference in cell division times between the two populations is due only to shortening of the G1/G0 phase
<disp-formula id="pcbi.1006664.e014"><alternatives><graphic xlink:href="pcbi.1006664.e014.jpg" id="pcbi.1006664.e014g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M14"><mml:mrow><mml:mi>T</mml:mi><mml:mo>&#x02212;</mml:mo><mml:msup><mml:mi>T</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo>=</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msubsup><mml:mi>T</mml:mi><mml:mn>1</mml:mn><mml:mo>*</mml:mo></mml:msubsup><mml:mo>=</mml:mo><mml:mo>&#x00394;</mml:mo></mml:mrow></mml:math></alternatives></disp-formula></p><p>Let us note that in the experiment described earlier on, we measure the ratios <inline-formula id="pcbi.1006664.e015"><alternatives><graphic xlink:href="pcbi.1006664.e015.jpg" id="pcbi.1006664.e015g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M15"><mml:mi>&#x003c6;</mml:mi></mml:math></alternatives></inline-formula> (G1/G0 fraction in Type I receptor cells) and <inline-formula id="pcbi.1006664.e016"><alternatives><graphic xlink:href="pcbi.1006664.e016.jpg" id="pcbi.1006664.e016g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M16"><mml:msup><mml:mrow><mml:mi>&#x003c6;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msup></mml:math></alternatives></inline-formula> (G1/G0 fraction in D 715 receptor cells). Following some algebra, we obtain an estimate of <inline-formula id="pcbi.1006664.e017"><alternatives><graphic xlink:href="pcbi.1006664.e017.jpg" id="pcbi.1006664.e017g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M17"><mml:mi mathvariant="normal">&#x00394;</mml:mi></mml:math></alternatives></inline-formula> in the terms of <inline-formula id="pcbi.1006664.e018"><alternatives><graphic xlink:href="pcbi.1006664.e018.jpg" id="pcbi.1006664.e018g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M18"><mml:mi>&#x003c6;</mml:mi></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006664.e019"><alternatives><graphic xlink:href="pcbi.1006664.e019.jpg" id="pcbi.1006664.e019g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M19"><mml:msup><mml:mrow><mml:mi>&#x003c6;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msup></mml:math></alternatives></inline-formula> given we assume <inline-formula id="pcbi.1006664.e020"><alternatives><graphic xlink:href="pcbi.1006664.e020.jpg" id="pcbi.1006664.e020g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M20"><mml:mi>T</mml:mi></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006664.e021"><alternatives><graphic xlink:href="pcbi.1006664.e021.jpg" id="pcbi.1006664.e021g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M21"><mml:mi>&#x003b1;</mml:mi></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006664.e022"><alternatives><graphic xlink:href="pcbi.1006664.e022.jpg" id="pcbi.1006664.e022g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M22"><mml:msup><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msup></mml:math></alternatives></inline-formula>
<disp-formula id="pcbi.1006664.e023"><alternatives><graphic xlink:href="pcbi.1006664.e023.jpg" id="pcbi.1006664.e023g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M23"><mml:mrow><mml:mi>&#x00394;</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>&#x003c8;</mml:mi><mml:mo>&#x02212;</mml:mo><mml:msup><mml:mi>&#x003c8;</mml:mi><mml:mo>*</mml:mo></mml:msup></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:msup><mml:mi>&#x003c8;</mml:mi><mml:mo>*</mml:mo></mml:msup></mml:mrow></mml:mfrac><mml:mi>T</mml:mi></mml:mrow></mml:math></alternatives></disp-formula>
where <inline-formula id="pcbi.1006664.e024"><alternatives><graphic xlink:href="pcbi.1006664.e024.jpg" id="pcbi.1006664.e024g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M24"><mml:mi>&#x003c8;</mml:mi></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006664.e025"><alternatives><graphic xlink:href="pcbi.1006664.e025.jpg" id="pcbi.1006664.e025g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M25"><mml:msup><mml:mrow><mml:mi>&#x003c8;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msup></mml:math></alternatives></inline-formula> have been already expressed in the terms of <inline-formula id="pcbi.1006664.e026"><alternatives><graphic xlink:href="pcbi.1006664.e026.jpg" id="pcbi.1006664.e026g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M26"><mml:mi>&#x003c6;</mml:mi></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006664.e027"><alternatives><graphic xlink:href="pcbi.1006664.e027.jpg" id="pcbi.1006664.e027g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M27"><mml:msup><mml:mrow><mml:mi>&#x003c6;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msup></mml:math></alternatives></inline-formula>.</p><p>Selective coefficient in the Moran model is defined as <inline-formula id="pcbi.1006664.e028"><alternatives><graphic xlink:href="pcbi.1006664.e028.jpg" id="pcbi.1006664.e028g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M28"><mml:mi>s</mml:mi><mml:mo>=</mml:mo><mml:mi>r</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:math></alternatives></inline-formula>, where <inline-formula id="pcbi.1006664.e029"><alternatives><graphic xlink:href="pcbi.1006664.e029.jpg" id="pcbi.1006664.e029g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M29"><mml:mi>r</mml:mi></mml:math></alternatives></inline-formula> is the ratio of probabilities that the replacent for a withdrawn (divided) self-renewing cell is a mutant (in this case an &#x0201c;asterisked&#x0201d; cell) and, respectively, wild-type. This interpretation is consistent with the confined environment of the bone marrow, in which on the average one progeny cell dies or differentiates, leaving the self-renewing cell pool. This leads to expression
<disp-formula id="pcbi.1006664.e030"><alternatives><graphic xlink:href="pcbi.1006664.e030.jpg" id="pcbi.1006664.e030g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M30"><mml:mrow><mml:mi>s</mml:mi><mml:mo>=</mml:mo><mml:mi>r</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mn>1</mml:mn><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mi>&#x003bb;</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo>&#x02212;</mml:mo><mml:mi>&#x003bb;</mml:mi></mml:mrow><mml:mi>&#x003bb;</mml:mi></mml:mfrac></mml:mrow></mml:math></alternatives></disp-formula></p><p>This interpretation allows understanding the bounds on the selection coefficient provided by the experiment. We accepted <inline-formula id="pcbi.1006664.e031"><alternatives><graphic xlink:href="pcbi.1006664.e031.jpg" id="pcbi.1006664.e031g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M31"><mml:mi>T</mml:mi><mml:mo>=</mml:mo><mml:mn>4</mml:mn></mml:math></alternatives></inline-formula> days, and we may start from assuming <inline-formula id="pcbi.1006664.e032"><alternatives><graphic xlink:href="pcbi.1006664.e032.jpg" id="pcbi.1006664.e032g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M32"><mml:mi>&#x003b1;</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:math></alternatives></inline-formula> (perfect division efficiency). Suppose that in approximate agreement with the experiment, we consider <inline-formula id="pcbi.1006664.e033"><alternatives><graphic xlink:href="pcbi.1006664.e033.jpg" id="pcbi.1006664.e033g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M33"><mml:mi>&#x003c6;</mml:mi><mml:mo>=</mml:mo><mml:mn>0.7</mml:mn></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006664.e034"><alternatives><graphic xlink:href="pcbi.1006664.e034.jpg" id="pcbi.1006664.e034g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M34"><mml:msup><mml:mrow><mml:mi>&#x003c6;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mn>0.66</mml:mn></mml:math></alternatives></inline-formula>, which leads to <inline-formula id="pcbi.1006664.e035"><alternatives><graphic xlink:href="pcbi.1006664.e035.jpg" id="pcbi.1006664.e035g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M35"><mml:mi>&#x003c8;</mml:mi><mml:mo>=</mml:mo><mml:mn>0.621</mml:mn></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006664.e036"><alternatives><graphic xlink:href="pcbi.1006664.e036.jpg" id="pcbi.1006664.e036g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M36"><mml:msup><mml:mrow><mml:mi>&#x003c8;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mn>0.567</mml:mn></mml:math></alternatives></inline-formula>, and to <inline-formula id="pcbi.1006664.e037"><alternatives><graphic xlink:href="pcbi.1006664.e037.jpg" id="pcbi.1006664.e037g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M37"><mml:mo>&#x00394;</mml:mo><mml:mo>=</mml:mo><mml:mn>0.503</mml:mn></mml:math></alternatives></inline-formula>. In turn, this provides <inline-formula id="pcbi.1006664.e038"><alternatives><graphic xlink:href="pcbi.1006664.e038.jpg" id="pcbi.1006664.e038g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M38"><mml:mi>&#x003bb;</mml:mi><mml:mo>=</mml:mo><mml:mn>0.173</mml:mn><mml:msup><mml:mrow><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006664.e039"><alternatives><graphic xlink:href="pcbi.1006664.e039.jpg" id="pcbi.1006664.e039g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M39"><mml:msup><mml:mrow><mml:mi>&#x003bb;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mn>0.198</mml:mn><mml:msup><mml:mrow><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></alternatives></inline-formula> which leads to <inline-formula id="pcbi.1006664.e040"><alternatives><graphic xlink:href="pcbi.1006664.e040.jpg" id="pcbi.1006664.e040g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M40"><mml:mi>s</mml:mi><mml:mo>=</mml:mo><mml:mn>0.144</mml:mn></mml:math></alternatives></inline-formula>. Lowering equally the division efficiencies of both cell types changes the selection coefficient only slightly. However, if the &#x0201c;asterisked&#x0201d; (mutant) efficiency is lowered to <inline-formula id="pcbi.1006664.e041"><alternatives><graphic xlink:href="pcbi.1006664.e041.jpg" id="pcbi.1006664.e041g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M41"><mml:msup><mml:mrow><mml:mi>&#x003b1;</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">*</mml:mi></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mn>0.93</mml:mn></mml:math></alternatives></inline-formula>, the selective advantage of faster proliferating cells shrinks to almost 0. Consistently with this, we use the range of <inline-formula id="pcbi.1006664.e042"><alternatives><graphic xlink:href="pcbi.1006664.e042.jpg" id="pcbi.1006664.e042g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M42"><mml:mi>s</mml:mi></mml:math></alternatives></inline-formula>-values from 0.005 to 0.1 (<xref rid="pcbi.1006664.t001" ref-type="table">Table 1</xref>) and from 0.008 to 0.02 (<bold><xref ref-type="fig" rid="pcbi.1006664.g002">Fig 2</xref></bold>), which stay below the upper bound provided by <inline-formula id="pcbi.1006664.e043"><alternatives><graphic xlink:href="pcbi.1006664.e043.jpg" id="pcbi.1006664.e043g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M43"><mml:mi>s</mml:mi><mml:mo>=</mml:mo><mml:mn>0.144</mml:mn></mml:math></alternatives></inline-formula>.</p><fig id="pcbi.1006664.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1006664.g002</object-id><label>Fig 2</label><caption><p><bold>(A)</bold> Age at which the d715 mutants replace the normal cells in the CMP compartment, as predicted by the modified Moran model with varying cell population size, for a range of mutation rate and selection coefficient values. <bold>(B)</bold> Selection coefficient values corresponding to the ages at replacement of 4 years old (solid line), 13 years old (dashed line), and 22 years old (dotted line) for a range of mutation rates values. <bold>(C)</bold> Mutant cell count at age of 1 year for a range of mutation rate values.</p></caption><graphic xlink:href="pcbi.1006664.g002"/></fig><table-wrap id="pcbi.1006664.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1006664.t001</object-id><label>Table 1</label><caption><title>Results of the computations of the expected time to fixation.</title></caption><alternatives><graphic id="pcbi.1006664.t001g" xlink:href="pcbi.1006664.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" style="border-bottom:thick" rowspan="1" colspan="1"><inline-formula id="pcbi.1006664.e044"><alternatives><graphic id="pcbi.1006664.e044g" xlink:href="pcbi.1006664.e044"/><mml:math id="M44"><mml:mi mathvariant="bold-italic">s</mml:mi></mml:math></alternatives></inline-formula></th><th align="center" style="border-bottom:thick" rowspan="1" colspan="1"><inline-formula id="pcbi.1006664.e045"><alternatives><graphic id="pcbi.1006664.e045g" xlink:href="pcbi.1006664.e045"/><mml:math id="M45"><mml:mi mathvariant="bold-italic">i</mml:mi></mml:math></alternatives></inline-formula></th><th align="center" style="border-bottom:thick" rowspan="1" colspan="1"><inline-formula id="pcbi.1006664.e046"><alternatives><graphic id="pcbi.1006664.e046g" xlink:href="pcbi.1006664.e046"/><mml:math id="M46"><mml:mi mathvariant="bold-italic">&#x003bc;</mml:mi></mml:math></alternatives></inline-formula><break/>(cell division<sup>-1</sup>)</th><th align="center" style="border-bottom:thick" rowspan="1" colspan="1"><inline-formula id="pcbi.1006664.e047"><alternatives><graphic id="pcbi.1006664.e047g" xlink:href="pcbi.1006664.e047"/><mml:math id="M47"><mml:mi mathvariant="bold-italic">E</mml:mi><mml:mo>[</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">T</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>|</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">T</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="bold-italic">N</mml:mi></mml:mrow></mml:msub><mml:mo>&#x0003c;</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="bold-italic">T</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>]</mml:mo></mml:math></alternatives></inline-formula><break/>(yr.)</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">0.005</td><td align="center" rowspan="1" colspan="1">240</td><td align="center" rowspan="1" colspan="1">2.01&#x000d7;10<sup>&#x02212;08</sup></td><td align="center" rowspan="1" colspan="1">90.57</td></tr><tr><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">120</td><td align="center" rowspan="1" colspan="1">1.00&#x000d7;10<sup>&#x02212;08</sup></td><td align="center" rowspan="1" colspan="1">46.05</td></tr><tr><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">60</td><td align="center" rowspan="1" colspan="1">4.99&#x000d7;10<sup>&#x02212;09</sup></td><td align="center" rowspan="1" colspan="1">23.41</td></tr><tr><td align="center" rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">3.31&#x000d7;10<sup>&#x02212;09</sup></td><td align="center" rowspan="1" colspan="1">15.75</td></tr><tr><td align="center" rowspan="1" colspan="1">0.04</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">2.47&#x000d7;10<sup>&#x02212;09</sup></td><td align="center" rowspan="1" colspan="1">11.90</td></tr><tr><td align="center" rowspan="1" colspan="1">0.05</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">1.97&#x000d7;10<sup>&#x02212;09</sup></td><td align="center" rowspan="1" colspan="1">9.57</td></tr><tr><td align="center" rowspan="1" colspan="1">0.1</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">9.57&#x000d7;10<sup>&#x02212;10</sup></td><td align="center" rowspan="1" colspan="1">4.86</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>Results of the computations of the expected time to fixation of a <italic>CSF3R</italic> truncation mutation with probability of fixation kept at <inline-formula id="pcbi.1006664.e048"><alternatives><graphic id="pcbi.1006664.e048g" xlink:href="pcbi.1006664.e048"/><mml:math id="M48"><mml:mi>P</mml:mi><mml:mo>[</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:msub><mml:mo>&#x0003c;</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>]</mml:mo><mml:mo>=</mml:mo><mml:mn>0.7</mml:mn></mml:math></alternatives></inline-formula>, assuming the Moran process with directional selection. Notation: <inline-formula id="pcbi.1006664.e049"><alternatives><graphic id="pcbi.1006664.e049g" xlink:href="pcbi.1006664.e049"/><mml:math id="M49"><mml:mi>s</mml:mi></mml:math></alternatives></inline-formula>, selection coefficient; <inline-formula id="pcbi.1006664.e050"><alternatives><graphic id="pcbi.1006664.e050g" xlink:href="pcbi.1006664.e050"/><mml:math id="M50"><mml:mi>i</mml:mi></mml:math></alternatives></inline-formula>, mutant count at birth; <inline-formula id="pcbi.1006664.e051"><alternatives><graphic id="pcbi.1006664.e051g" xlink:href="pcbi.1006664.e051"/><mml:math id="M51"><mml:mi>&#x003bc;</mml:mi></mml:math></alternatives></inline-formula>, mutation rate (cell division<sup>-1</sup>). <inline-formula id="pcbi.1006664.e052"><alternatives><graphic id="pcbi.1006664.e052g" xlink:href="pcbi.1006664.e052"/><mml:math id="M52"><mml:mi>E</mml:mi><mml:mo>[</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>|</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:msub><mml:mo>&#x0003c;</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>]</mml:mo></mml:math></alternatives></inline-formula> is the age at fixation of the <italic>CSF3R</italic> truncation mutant (yr). For detailed hypotheses and derivations, see the present section.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec005"><title>Effect of CSF3R (wild type vs. D715) on cell proliferation</title><p>Ba/F3 cells expressing either wild type (Type I) or mutant (D715) <italic>CSF3R</italic> were treated with increasing doses of G-CSF (ng/ml) and proliferation was measured using the MTT assay performed in triplicates in a 96 well plate. Full account of experimental procedures is found in the <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold>. The data are raw absorbance values at 600 nm and represent the three replicates plotted against increasing dose of G-CSF.</p><p>Concerning recalculation from the pharmacological dose to serum concentration of the G-CSF, ref.[<xref rid="pcbi.1006664.ref036" ref-type="bibr">36</xref>] is providing relevant information. In this publication, see their <bold><xref ref-type="fig" rid="pcbi.1006664.g001">Fig 1</xref></bold>, therapeutic doses from <inline-formula id="pcbi.1006664.e053"><alternatives><graphic xlink:href="pcbi.1006664.e053.jpg" id="pcbi.1006664.e053g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M53"><mml:mn>5</mml:mn><mml:mo>&#x02013;</mml:mo><mml:mn>15</mml:mn><mml:mspace width="0.25em"/><mml:mo>&#x003bc;</mml:mo><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">k</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:math></alternatives></inline-formula> body weight resulted in serum concentrations of the order from <inline-formula id="pcbi.1006664.e054"><alternatives><graphic xlink:href="pcbi.1006664.e054.jpg" id="pcbi.1006664.e054g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M54"><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mn>100</mml:mn><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:math></alternatives></inline-formula>, with a maximum for the lowest dose of <inline-formula id="pcbi.1006664.e055"><alternatives><graphic xlink:href="pcbi.1006664.e055.jpg" id="pcbi.1006664.e055g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M55"><mml:mn>5</mml:mn><mml:mspace width="0.25em"/><mml:mo>&#x003bc;</mml:mo><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">k</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:math></alternatives></inline-formula> reached after 4 hours and equal to over <inline-formula id="pcbi.1006664.e056"><alternatives><graphic xlink:href="pcbi.1006664.e056.jpg" id="pcbi.1006664.e056g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M56"><mml:mn>10</mml:mn><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:math></alternatives></inline-formula>, and remaining over <inline-formula id="pcbi.1006664.e057"><alternatives><graphic xlink:href="pcbi.1006664.e057.jpg" id="pcbi.1006664.e057g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M57"><mml:mn>1</mml:mn><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:math></alternatives></inline-formula> for 10 days.</p><p>To better understand the data, we performed parametric least-square fitting of the Type 1 and D715 data using Hill-like sigmoid curves, which results in clarified visualization of trends with the two curves crossing approximately at G-CSF concentration of <inline-formula id="pcbi.1006664.e058"><alternatives><graphic xlink:href="pcbi.1006664.e058.jpg" id="pcbi.1006664.e058g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M58"><mml:mn>0.1</mml:mn><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">g</mml:mi></mml:math></alternatives></inline-formula>. Hill equation is a prototypical sigmoidal curve widely used in systems biology [<xref rid="pcbi.1006664.ref037" ref-type="bibr">37</xref>]. It has the form
<disp-formula id="pcbi.1006664.e059"><alternatives><graphic xlink:href="pcbi.1006664.e059.jpg" id="pcbi.1006664.e059g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M59"><mml:mrow><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi>a</mml:mi><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mtext>ln</mml:mtext><mml:mi>x</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>c</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mi>n</mml:mi></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mtext>ln</mml:mtext><mml:mi>x</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>c</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mi>n</mml:mi></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>b</mml:mi><mml:mi>n</mml:mi></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:math></alternatives></disp-formula></p><p>The best least-square fit to the data (separately for Type I and D715 data). Values of estimated coefficients: Common for Type I and D715, <inline-formula id="pcbi.1006664.e060"><alternatives><graphic xlink:href="pcbi.1006664.e060.jpg" id="pcbi.1006664.e060g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M60"><mml:msub><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0.349</mml:mn></mml:math></alternatives></inline-formula>; Type 1, <italic>a</italic> = 0.449, <italic>b</italic> = 20.802, <italic>c</italic> = -23.309, <italic>n</italic> = 11.149; D715, <italic>a</italic> = 0.479, <italic>b</italic> = 21.075, <italic>c</italic> = -23.278, <italic>n</italic> = 28.255.</p><p>In addition, we carried out rigorous testing using one-sided Wilcoxon two-sample rank test of the difference between the Type 1 and D715 data points separately for concentrations <inline-formula id="pcbi.1006664.e061"><alternatives><graphic xlink:href="pcbi.1006664.e061.jpg" id="pcbi.1006664.e061g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M61"><mml:mo>&#x0003e;</mml:mo><mml:mn>0.1</mml:mn><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:math></alternatives></inline-formula> (resulting in highly significant difference at <inline-formula id="pcbi.1006664.e062"><alternatives><graphic xlink:href="pcbi.1006664.e062.jpg" id="pcbi.1006664.e062g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M62"><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.0034</mml:mn></mml:math></alternatives></inline-formula>), and for concentrations <inline-formula id="pcbi.1006664.e063"><alternatives><graphic xlink:href="pcbi.1006664.e063.jpg" id="pcbi.1006664.e063g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M63"><mml:mo>&#x02264;</mml:mo><mml:mn>0.1</mml:mn><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:math></alternatives></inline-formula> (resulting in borderline significant difference in opposite direction at <inline-formula id="pcbi.1006664.e064"><alternatives><graphic xlink:href="pcbi.1006664.e064.jpg" id="pcbi.1006664.e064g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M64"><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mn>0.089</mml:mn></mml:math></alternatives></inline-formula>). This testing justifies the assertion of higher growth rate of D715 cell in the range of G-CSF concentrations above <inline-formula id="pcbi.1006664.e065"><alternatives><graphic xlink:href="pcbi.1006664.e065.jpg" id="pcbi.1006664.e065g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M65"><mml:mn>0.1</mml:mn><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mo>/</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:math></alternatives></inline-formula>.</p></sec></sec><sec id="sec006"><title>Proof-of-principle model</title><sec id="sec007"><title>Moran process with directional selection</title><p>For a simplified proof-of-principle model of competition between mutant and wild type cells in adult bone marrow, we use the standard Moran process with selection [<xref rid="pcbi.1006664.ref038" ref-type="bibr">38</xref>]. In this process (<bold><xref ref-type="fig" rid="pcbi.1006664.g003">Fig 3</xref></bold>), the population of granulocyte precursors is assumed to be constant, with the proportion of mutants varying in time, and time running in discrete units (such as days or cell-division times). We consider a population of <inline-formula id="pcbi.1006664.e066"><alternatives><graphic xlink:href="pcbi.1006664.e066.jpg" id="pcbi.1006664.e066g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M66"><mml:mi>N</mml:mi></mml:math></alternatives></inline-formula> biological cells, which at time 0 contains <inline-formula id="pcbi.1006664.e067"><alternatives><graphic xlink:href="pcbi.1006664.e067.jpg" id="pcbi.1006664.e067g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M67"><mml:mi>i</mml:mi></mml:math></alternatives></inline-formula> mutant cells. The mutant has a selective advantage defined as the relative fitness <inline-formula id="pcbi.1006664.e068"><alternatives><graphic xlink:href="pcbi.1006664.e068.jpg" id="pcbi.1006664.e068g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M68"><mml:mi>r</mml:mi></mml:math></alternatives></inline-formula>, which is frequently expressed as <inline-formula id="pcbi.1006664.e069"><alternatives><graphic xlink:href="pcbi.1006664.e069.jpg" id="pcbi.1006664.e069g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M69"><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>s</mml:mi></mml:math></alternatives></inline-formula>, where <inline-formula id="pcbi.1006664.e070"><alternatives><graphic xlink:href="pcbi.1006664.e070.jpg" id="pcbi.1006664.e070g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M70"><mml:mi>s</mml:mi></mml:math></alternatives></inline-formula> is called the selection coefficient. For an advantageous mutant, <inline-formula id="pcbi.1006664.e071"><alternatives><graphic xlink:href="pcbi.1006664.e071.jpg" id="pcbi.1006664.e071g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M71"><mml:mi>r</mml:mi><mml:mo>&#x0003e;</mml:mo><mml:mn>1</mml:mn></mml:math></alternatives></inline-formula>, or <inline-formula id="pcbi.1006664.e072"><alternatives><graphic xlink:href="pcbi.1006664.e072.jpg" id="pcbi.1006664.e072g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M72"><mml:mi>s</mml:mi><mml:mo>&#x0003e;</mml:mo><mml:mn>0</mml:mn></mml:math></alternatives></inline-formula>. Further details are found in the corresponding section of the <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold>.</p><fig id="pcbi.1006664.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1006664.g003</object-id><label>Fig 3</label><caption><title>Moran Process with discrete time and directional selection.</title><p>One of the <inline-formula id="pcbi.1006664.e073"><alternatives><graphic id="pcbi.1006664.e073g" xlink:href="pcbi.1006664.e073"/><mml:math id="M73"><mml:mi>N</mml:mi></mml:math></alternatives></inline-formula> cells (<inline-formula id="pcbi.1006664.e074"><alternatives><graphic id="pcbi.1006664.e074g" xlink:href="pcbi.1006664.e074"/><mml:math id="M74"><mml:mi>i</mml:mi></mml:math></alternatives></inline-formula> mutants, in orange, and <inline-formula id="pcbi.1006664.e075"><alternatives><graphic id="pcbi.1006664.e075g" xlink:href="pcbi.1006664.e075"/><mml:math id="M75"><mml:mi>N</mml:mi><mml:mo>&#x02013;</mml:mo><mml:mi>i</mml:mi></mml:math></alternatives></inline-formula> wildtype, in green), present at time <inline-formula id="pcbi.1006664.e076"><alternatives><graphic id="pcbi.1006664.e076g" xlink:href="pcbi.1006664.e076"/><mml:math id="M76"><mml:mi>t</mml:mi></mml:math></alternatives></inline-formula>, dies (no preference for type). Its replacement at time <inline-formula id="pcbi.1006664.e077"><alternatives><graphic id="pcbi.1006664.e077g" xlink:href="pcbi.1006664.e077"/><mml:math id="M77"><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:math></alternatives></inline-formula> is selected from all cells present at <inline-formula id="pcbi.1006664.e078"><alternatives><graphic id="pcbi.1006664.e078g" xlink:href="pcbi.1006664.e078"/><mml:math id="M78"><mml:mi>t</mml:mi></mml:math></alternatives></inline-formula>, with odds (relative fitness) <italic>r</italic> in favor of the mutant. Relative fitness is frequently expressed as <inline-formula id="pcbi.1006664.e079"><alternatives><graphic id="pcbi.1006664.e079g" xlink:href="pcbi.1006664.e079"/><mml:math id="M79"><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>s</mml:mi></mml:math></alternatives></inline-formula>, where <inline-formula id="pcbi.1006664.e080"><alternatives><graphic id="pcbi.1006664.e080g" xlink:href="pcbi.1006664.e080"/><mml:math id="M80"><mml:mi>s</mml:mi></mml:math></alternatives></inline-formula> is called the selection coefficient. For an advantageous mutant, <inline-formula id="pcbi.1006664.e081"><alternatives><graphic id="pcbi.1006664.e081g" xlink:href="pcbi.1006664.e081"/><mml:math id="M81"><mml:mi>r</mml:mi><mml:mo>&#x0003e;</mml:mo><mml:mn>1</mml:mn></mml:math></alternatives></inline-formula>, or <inline-formula id="pcbi.1006664.e082"><alternatives><graphic id="pcbi.1006664.e082g" xlink:href="pcbi.1006664.e082"/><mml:math id="M82"><mml:mi>s</mml:mi><mml:mo>&#x0003e;</mml:mo><mml:mn>0</mml:mn></mml:math></alternatives></inline-formula>.</p></caption><graphic xlink:href="pcbi.1006664.g003"/></fig></sec><sec id="sec008"><title>Selective advantage in cycling cells</title><p>CSF3R is a member of the hematopoietin/cytokine receptor family and functions as a homodimer. The cytoplasmic region consists of a proximal domain essential for proliferation and a distal domain critical for differentiation. Acquired CSF3R mutations have been observed to cluster between nucleotides 2384 to 2522 (residues 715 to 750), resulting in the loss of the distal domain [<xref rid="pcbi.1006664.ref023" ref-type="bibr">23</xref>]. Epidemiological studies demonstrated that the risk of sMDS/AML increased with the dose of G-CSF [<xref rid="pcbi.1006664.ref016" ref-type="bibr">16</xref>, <xref rid="pcbi.1006664.ref039" ref-type="bibr">39</xref>].</p><p>Mutant clones may divide more frequently and/or be less apoptotic. In the simplest case of no cell death, selective advantage can be related to shortening of the interdivision times in mutant cells, relative to normal cells. A proxy for shorter interdivision time is a lower proportion of cells in the G1 phase, as this phase is usually most variable. <bold><xref ref-type="fig" rid="pcbi.1006664.g001">Fig 1A</xref></bold> presents a summary of the dynamics of cell cycle distribution of Ba/F3 cells expressing either the full-length wild type CSF3R or the CSF3R D715 mutant following their release from a starvation block. The fraction of cells in G1 in D715 mutants is lower by about 0.05 compared to that in the wild type CSF3R expressing cells, which translates into a growth rate advantage of the CSF3R D715 mutant. The difference is highly statistically significant, as flow cytometry measures thousands of cells per condition.</p><p>As an independent check, <bold><xref ref-type="fig" rid="pcbi.1006664.g001">Fig 1B</xref></bold> shows a direct comparison of growth curves of Ba/F3 cells expressing either the full-length CSF3R or the truncated CSF3R D715. The dose dependence shows that mutants have a selective advantage over a range of high G-CSF concentrations, whereas for low (normal) concentrations, they are at best neutral or possibly disadvantageous. Relevant laboratory techniques are found in <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold>. Similar results were found depending on the particular CSF3R cytoplasmic mutant [<xref rid="pcbi.1006664.ref040" ref-type="bibr">40</xref>].</p></sec><sec id="sec009"><title>CSF3R truncation mutations at the fetal-life expansion phase of bone marrow</title><p>Hematopoiesis in the human fetus moves from the liver into bone marrow about 90 days before the end of the pregnancy [<xref rid="pcbi.1006664.ref041" ref-type="bibr">41</xref>, <xref rid="pcbi.1006664.ref042" ref-type="bibr">42</xref>]. The requirement of more than one mutant cell present at time <italic>t</italic> = 0 of the Moran process can be satisfied as follows. Suppose that <italic>CSF3R</italic> truncation mutations occur during the embryonic bone marrow expansion stage. In this time interval, because of the rapid expansion on the bone marrow, cell proliferation and mutation can be described using the time-continuous Markov branching process model [<xref rid="pcbi.1006664.ref008" ref-type="bibr">8</xref>], originally developed by Coldman and Goldie in a different context [<xref rid="pcbi.1006664.ref043" ref-type="bibr">43</xref>, <xref rid="pcbi.1006664.ref044" ref-type="bibr">44</xref>]. The assumptions are as follows (<bold><xref ref-type="fig" rid="pcbi.1006664.g004">Fig 4</xref></bold>):</p><fig id="pcbi.1006664.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1006664.g004</object-id><label>Fig 4</label><caption><title>The branching process of cell proliferation with irreversible mutation.</title><p>Briefly, the cancer cell population is initiated by a single &#x0201c;wild type&#x0201d; (WT) cell, denoted as &#x0201c;0&#x0201d;. At each division, with probability <inline-formula id="pcbi.1006664.e083"><alternatives><graphic id="pcbi.1006664.e083g" xlink:href="pcbi.1006664.e083"/><mml:math id="M83"><mml:mi>&#x003bc;</mml:mi></mml:math></alternatives></inline-formula>, one of the WT progeny cells mutates. Mutants, denoted as &#x0201c;1&#x0201d; produce a pair of mutant progeny. Mutants have the same distribution of the interdivision time as the WT cells.</p></caption><graphic xlink:href="pcbi.1006664.g004"/></fig><list list-type="order"><list-item><p>The stem cell population (here, pooled Hematopoietic Stem Cells or HSC, and Common Myeloid Progenitors or CMP) is initiated by a small number <inline-formula id="pcbi.1006664.e084"><alternatives><graphic xlink:href="pcbi.1006664.e084.jpg" id="pcbi.1006664.e084g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M84"><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></alternatives></inline-formula> of &#x0201c;wild type&#x0201d; (WT) cell that already acquired the <italic>ELANE</italic> mutation.</p></list-item><list-item><p>Interdivision time of WT cells is a random variable from an exponential distribution with parameter <inline-formula id="pcbi.1006664.e085"><alternatives><graphic xlink:href="pcbi.1006664.e085.jpg" id="pcbi.1006664.e085g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M85"><mml:mi>&#x003bb;</mml:mi></mml:math></alternatives></inline-formula>. Accordingly, mean interdivision time of WT cells is equal to <inline-formula id="pcbi.1006664.e086"><alternatives><graphic xlink:href="pcbi.1006664.e086.jpg" id="pcbi.1006664.e086g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M86"><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mi>&#x003bb;</mml:mi></mml:math></alternatives></inline-formula>.</p></list-item><list-item><p>At each division of a WT cell, with probability <inline-formula id="pcbi.1006664.e087"><alternatives><graphic xlink:href="pcbi.1006664.e087.jpg" id="pcbi.1006664.e087g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M87"><mml:mi>&#x003bc;</mml:mi></mml:math></alternatives></inline-formula>, one of the progeny cells acquires the <italic>CSF3R D715</italic> mutation. <italic>CSF3R</italic> truncation mutants always produce <italic>CSF3R</italic> truncation mutants when dividing.</p></list-item><list-item><p>At the expansion phase, mutants are assumed selectively neutral (have the same parameter <inline-formula id="pcbi.1006664.e088"><alternatives><graphic xlink:href="pcbi.1006664.e088.jpg" id="pcbi.1006664.e088g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M88"><mml:mi>&#x003bb;</mml:mi></mml:math></alternatives></inline-formula> as WT cells).</p></list-item></list><p>Mathematical details are found in the corresponding section of the <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold>.</p></sec></sec><sec id="sec010"><title>Comprehensive model of fixation of CSF3R truncation mutants</title><sec id="sec011"><title>Modeling the age-dependent changes of sizes of the bone marrow cell compartments</title><p>For more precise simulations, we build a model of dynamics of the hematopoietic stem cells (HSC) these latter more properly defined as HSC and long term culture-initiating cells (LTC-IC) [<xref rid="pcbi.1006664.ref045" ref-type="bibr">45</xref>], and of the common myeloid progenitors (CMP), which give rise to neutrophils and/or monocytes. The model schematic is depicted in <bold><xref ref-type="fig" rid="pcbi.1006664.g005">Fig 5</xref></bold>. Dynamics of these cell populations are represented in the compartmental model by a system of three differential equations following the model of Arino and Kimmel [<xref rid="pcbi.1006664.ref046" ref-type="bibr">46</xref>]. The equations of the model are explained in the corresponding section of the <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold> and in the legends to <bold>Figs <xref ref-type="fig" rid="pcbi.1006664.g005">5</xref></bold>and <bold><xref ref-type="fig" rid="pcbi.1006664.g006">6</xref>.</bold></p><fig id="pcbi.1006664.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1006664.g005</object-id><label>Fig 5</label><caption><title>Deterministic model of age-related dynamics of pluripotent and committed cells and granulocytes.</title><p><inline-formula id="pcbi.1006664.e089"><alternatives><graphic id="pcbi.1006664.e089g" xlink:href="pcbi.1006664.e089"/><mml:math id="M89"><mml:mi>P</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula>, <inline-formula id="pcbi.1006664.e090"><alternatives><graphic id="pcbi.1006664.e090g" xlink:href="pcbi.1006664.e090"/><mml:math id="M90"><mml:mi>C</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula>, and <inline-formula id="pcbi.1006664.e091"><alternatives><graphic id="pcbi.1006664.e091g" xlink:href="pcbi.1006664.e091"/><mml:math id="M91"><mml:mi>G</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula> are the numbers of pluripotent cells (HSC compartment), committed cells (CMP compartment), and peripheral granulocytes at time <inline-formula id="pcbi.1006664.e092"><alternatives><graphic id="pcbi.1006664.e092g" xlink:href="pcbi.1006664.e092"/><mml:math id="M92"><mml:mi>t</mml:mi></mml:math></alternatives></inline-formula>, respectively; <inline-formula id="pcbi.1006664.e093"><alternatives><graphic id="pcbi.1006664.e093g" xlink:href="pcbi.1006664.e093"/><mml:math id="M93"><mml:mi>m</mml:mi></mml:math></alternatives></inline-formula> is the ratio of the committed cells in the hematopoietic cell lineage associated with the granulocyte line (assumed to be <inline-formula id="pcbi.1006664.e094"><alternatives><graphic id="pcbi.1006664.e094g" xlink:href="pcbi.1006664.e094"/><mml:math id="M94"><mml:mi>m</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>4</mml:mn><mml:mo>)</mml:mo><mml:mo>;</mml:mo><mml:mi>a</mml:mi></mml:math></alternatives></inline-formula>and <inline-formula id="pcbi.1006664.e095"><alternatives><graphic id="pcbi.1006664.e095g" xlink:href="pcbi.1006664.e095"/><mml:math id="M95"><mml:mi>c</mml:mi></mml:math></alternatives></inline-formula> are the proliferation rate and self-renewal probability of the <inline-formula id="pcbi.1006664.e096"><alternatives><graphic id="pcbi.1006664.e096g" xlink:href="pcbi.1006664.e096"/><mml:math id="M96"><mml:mi>P</mml:mi></mml:math></alternatives></inline-formula> cells; and, similarly, <inline-formula id="pcbi.1006664.e097"><alternatives><graphic id="pcbi.1006664.e097g" xlink:href="pcbi.1006664.e097"/><mml:math id="M97"><mml:mi>b</mml:mi></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006664.e098"><alternatives><graphic id="pcbi.1006664.e098g" xlink:href="pcbi.1006664.e098"/><mml:math id="M98"><mml:mi>d</mml:mi></mml:math></alternatives></inline-formula> are the proliferation rate and self-renewal probability of the <inline-formula id="pcbi.1006664.e099"><alternatives><graphic id="pcbi.1006664.e099g" xlink:href="pcbi.1006664.e099"/><mml:math id="M99"><mml:mi>C</mml:mi></mml:math></alternatives></inline-formula> cells. <inline-formula id="pcbi.1006664.e100"><alternatives><graphic id="pcbi.1006664.e100g" xlink:href="pcbi.1006664.e100"/><mml:math id="M100"><mml:mi>E</mml:mi><mml:mo>(</mml:mo><mml:mi>T</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula> denotes expected interdivision time of a cell.</p></caption><graphic xlink:href="pcbi.1006664.g005"/></fig><fig id="pcbi.1006664.g006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1006664.g006</object-id><label>Fig 6</label><caption><title>Estimated dynamics of human hematopoiesis in the bone marrow, starting from its onset in the final weeks of fetal life.</title><p>(For additional details see the twin sections titled <italic>Estimates of the parameters of the model of age-dependent dynamics of the granulocyte arm of the hematopoietic system</italic>, in the Results and in the <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold>). (A) Counts of the HSCs (<inline-formula id="pcbi.1006664.e101"><alternatives><graphic id="pcbi.1006664.e101g" xlink:href="pcbi.1006664.e101"/><mml:math id="M101"><mml:mi>P</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula>) and CMPs (<inline-formula id="pcbi.1006664.e102"><alternatives><graphic id="pcbi.1006664.e102g" xlink:href="pcbi.1006664.e102"/><mml:math id="M102"><mml:mi>C</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula>), and the rate of granulocyte production per day (<inline-formula id="pcbi.1006664.e103"><alternatives><graphic id="pcbi.1006664.e103g" xlink:href="pcbi.1006664.e103"/><mml:math id="M103"><mml:mi>&#x003b2;</mml:mi><mml:mi>G</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula>), as a function of time (individual&#x02019;s age), calculated for human body weight following the Theron&#x02019;s formula. (B) Time (individual&#x02019;s age) dependent parameters of the mathematical model of the human hematopoietic system: expected time (days) between HSC divisions <inline-formula id="pcbi.1006664.e104"><alternatives><graphic id="pcbi.1006664.e104g" xlink:href="pcbi.1006664.e104"/><mml:math id="M104"><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mi>a</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula>, expected time (days) between CMP divisions <inline-formula id="pcbi.1006664.e105"><alternatives><graphic id="pcbi.1006664.e105g" xlink:href="pcbi.1006664.e105"/><mml:math id="M105"><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>C</mml:mi></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mi>b</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula>, maturation probability of the HSC <inline-formula id="pcbi.1006664.e106"><alternatives><graphic id="pcbi.1006664.e106g" xlink:href="pcbi.1006664.e106"/><mml:math id="M106"><mml:mi>c</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula>, and differentiation probability of the CMP, <inline-formula id="pcbi.1006664.e107"><alternatives><graphic id="pcbi.1006664.e107g" xlink:href="pcbi.1006664.e107"/><mml:math id="M107"><mml:mi>d</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula>. Ratio of the committed cells in the hematopoietic cell lineage associated with the granulocyte lineage is assumed equal to <inline-formula id="pcbi.1006664.e108"><alternatives><graphic id="pcbi.1006664.e108g" xlink:href="pcbi.1006664.e108"/><mml:math id="M108"><mml:mi>m</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>4</mml:mn></mml:math></alternatives></inline-formula> for all ages. Please note the log-log scale of the graphs.</p></caption><graphic xlink:href="pcbi.1006664.g006"/></fig><p>Our model is consistent with the lifetime changes in the bone marrow volume and the HSC interdivision times [<xref rid="pcbi.1006664.ref047" ref-type="bibr">47</xref>, <xref rid="pcbi.1006664.ref048" ref-type="bibr">48</xref>], distinguishes between the periods before and after birth, and accounts for the body mass and HSC proliferation changes during childhood and adulthood. This requires that some of the model parameters change with time <inline-formula id="pcbi.1006664.e109"><alternatives><graphic xlink:href="pcbi.1006664.e109.jpg" id="pcbi.1006664.e109g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M109"><mml:mi>t</mml:mi></mml:math></alternatives></inline-formula> (individual&#x02019;s age). We found that it is sufficient to vary (i) the mean interdivision time of the HSC equal to <inline-formula id="pcbi.1006664.e110"><alternatives><graphic xlink:href="pcbi.1006664.e110.jpg" id="pcbi.1006664.e110g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M110"><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>p</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mi>a</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula>, (ii) the maturation probability of the HSC equal to <italic><inline-formula id="pcbi.1006664.e111"><alternatives><graphic xlink:href="pcbi.1006664.e111.jpg" id="pcbi.1006664.e111g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M111"><mml:mi>c</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula></italic>, and (iii) the differentiation probability of the CMP equal to <italic><inline-formula id="pcbi.1006664.e112"><alternatives><graphic xlink:href="pcbi.1006664.e112.jpg" id="pcbi.1006664.e112g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M112"><mml:mi>d</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula></italic>. See <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold> for explanation of mathematical symbols. The time (age) patterns of these and other coefficients that fit the data in refs. [<xref rid="pcbi.1006664.ref047" ref-type="bibr">47</xref>, <xref rid="pcbi.1006664.ref048" ref-type="bibr">48</xref>], are depicted in <bold><xref ref-type="fig" rid="pcbi.1006664.g006">Fig 6B</xref></bold>.</p><p>The model accommodates two apparently contradictory observations in the data viz. that (i) the interdivision times of the HSC dramatically increase over the lifetime, and (ii) the granulocyte volume remains proportional to the body weight [<xref rid="pcbi.1006664.ref047" ref-type="bibr">47</xref>, <xref rid="pcbi.1006664.ref048" ref-type="bibr">48</xref>]. Surprisingly, this can be achieved by relatively small changes in the cell maturation and differentiation coefficients. In the real-life system, this is accomplished by nonlinear regulatory feedbacks, with possible configurations similar as in ref. [<xref rid="pcbi.1006664.ref045" ref-type="bibr">45</xref>]. However, for our purposes, it is sufficient to assume that differentiation coefficients <inline-formula id="pcbi.1006664.e113"><alternatives><graphic xlink:href="pcbi.1006664.e113.jpg" id="pcbi.1006664.e113g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M113"><mml:mi>c</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006664.e114"><alternatives><graphic xlink:href="pcbi.1006664.e114.jpg" id="pcbi.1006664.e114g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M114"><mml:mi>d</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula> vary with time (<bold><xref ref-type="fig" rid="pcbi.1006664.g006">Fig 6B</xref></bold>). Mathematical details and parameter estimates are found in the corresponding sections of the <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold>.</p></sec><sec id="sec012"><title>Model of expansion of the CSF3R truncation mutant in the bone marrow in the form of the Moran process with variable population size, directional selection, and recurrent mutation</title><p>In contrast to the standard Moran process, this model assumes that the population size (cell count) <italic>N(t)</italic> varies in time. The population consists of cells of two types: wild type (WT; cells that already acquired the <italic>ELANE</italic> mutation) and <italic>CSF3R</italic> truncation mutants (M). For the WT-cells and M-cells equally, life lengths depend on individual&#x02019;s age. Upon death of a cell, another randomly chosen cell proliferates. Selective advantage is represented by a bias in choice of proliferating cell (as in the standard Moran model. WT-cell may irreversibly mutate into a M-cell at rate <inline-formula id="pcbi.1006664.e115"><alternatives><graphic xlink:href="pcbi.1006664.e115.jpg" id="pcbi.1006664.e115g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M115"><mml:mi>&#x003bc;</mml:mi></mml:math></alternatives></inline-formula>. Mathematical details are found in the corresponding section of the <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold>.</p><p>Technically, the model is limited to the CMP compartment of the bone marrow, since (1) cells in this compartment respond to G-CSF signaling as opposed to the HSC, which most likely do not, and (2) CMP compartment is much larger than the HSC one. Further stages of granulocyte precursors are assumed to only transmit the descendants of the mutated cells into peripheral blood and tissue and not to have even limited self-renewal properties. Before the GCS-F treatment is initiated, the mutants do not have selective advantage (i.e. <inline-formula id="pcbi.1006664.e116"><alternatives><graphic xlink:href="pcbi.1006664.e116.jpg" id="pcbi.1006664.e116g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M116"><mml:mi>s</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></alternatives></inline-formula>). Advantage appears at the time G-CSF treatment is administered, assumed to be six months after birth.</p></sec></sec></sec><sec sec-type="results" id="sec013"><title>Results</title><sec id="sec014"><title>Proof-of-principle model</title><sec id="sec015"><title>Mutation rate, selection and age at sMDS onset in the proof-of-principle model</title><p>In this section, we consider a simple Moran model with the mutants being cells carrying the <italic>CSF3R</italic> truncation mutation. Since around 70% of sMDS associated with SCN carry this mutation, this means that fixation of the mutant (i.e., elimination of the wild-type <italic>CSF3R</italic> in the SCN population) occurs with probability 0.7 (ref. [<xref rid="pcbi.1006664.ref023" ref-type="bibr">23</xref>]). Assuming this and a given selection coefficient of the mutant over the wild type, we calculate (see <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold>) the expected time to fixation and the required number of mutant cells at time 0 of the model (corresponding to birth of the individual). <bold><xref rid="pcbi.1006664.t001" ref-type="table">Table 1</xref></bold>presents results of the computations of the expected time to fixation of a <italic>CSF3R</italic> truncation mutation with probability of fixation kept at <inline-formula id="pcbi.1006664.e117"><alternatives><graphic xlink:href="pcbi.1006664.e117.jpg" id="pcbi.1006664.e117g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M117"><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mi>P</mml:mi><mml:mo>[</mml:mo><mml:mi>f</mml:mi><mml:mi>i</mml:mi><mml:mi>x</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mo>]</mml:mo><mml:mo>=</mml:mo><mml:mn>0.7</mml:mn></mml:math></alternatives></inline-formula>, assuming the Moran process with directional selection. The parameter values are consistent with the adolescent phase values in the accurate model of bone marrow expansion, as well as with the experiment-based estimates of the selective advantage of cells harboring the <italic>CSF3R</italic> truncation mutation, as outlined further on.</p></sec><sec id="sec016"><title>Determination of the expected time to fixation of the CSF3R truncation mutant and the required count of mutant-harboring cells at the end of fetal bone marrow expansion</title><p>Expected times to fixation of the <italic>CSF3R</italic> truncation mutant were computed by first solving Eq. (1) in the <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold> to find the initial count <inline-formula id="pcbi.1006664.e118"><alternatives><graphic xlink:href="pcbi.1006664.e118.jpg" id="pcbi.1006664.e118g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M118"><mml:mi>i</mml:mi></mml:math></alternatives></inline-formula> of mutants required for <inline-formula id="pcbi.1006664.e119"><alternatives><graphic xlink:href="pcbi.1006664.e119.jpg" id="pcbi.1006664.e119g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M119"><mml:mi>P</mml:mi><mml:mo>=</mml:mo><mml:mn>0.7</mml:mn></mml:math></alternatives></inline-formula>, given the summary number of HSC and CMP cells <inline-formula id="pcbi.1006664.e120"><alternatives><graphic xlink:href="pcbi.1006664.e120.jpg" id="pcbi.1006664.e120g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M120"><mml:mi>N</mml:mi></mml:math></alternatives></inline-formula> = 1.98&#x000d7;10<sup>8</sup> cells/kg &#x000d7;75 kg (the average adult body weight) and selection coefficient <inline-formula id="pcbi.1006664.e121"><alternatives><graphic xlink:href="pcbi.1006664.e121.jpg" id="pcbi.1006664.e121g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M121"><mml:mi>s</mml:mi></mml:math></alternatives></inline-formula> varying in a wide range.</p><p>In mathematical terms, if the probability of fixation of the mutant is provided by the Eq. (1) in the <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold>
<disp-formula id="pcbi.1006664.e122"><alternatives><graphic xlink:href="pcbi.1006664.e122.jpg" id="pcbi.1006664.e122g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M122"><mml:mrow><mml:mi>P</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mi>N</mml:mi></mml:msub><mml:mo>&#x0003c;</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mn>0</mml:mn></mml:msub></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mi>s</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mi>i</mml:mi></mml:msup></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mi>s</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mi>N</mml:mi></mml:msup></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives></disp-formula>
and for large <inline-formula id="pcbi.1006664.e123"><alternatives><graphic xlink:href="pcbi.1006664.e123.jpg" id="pcbi.1006664.e123g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M123"><mml:mi>N</mml:mi></mml:math></alternatives></inline-formula> and small <inline-formula id="pcbi.1006664.e124"><alternatives><graphic xlink:href="pcbi.1006664.e124.jpg" id="pcbi.1006664.e124g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M124"><mml:mi>i</mml:mi></mml:math></alternatives></inline-formula>, the expected time to fixation (given that fixation occurs), is asymptotically equivalent to [<xref rid="pcbi.1006664.ref038" ref-type="bibr">38</xref>]
<disp-formula id="pcbi.1006664.e125"><alternatives><graphic xlink:href="pcbi.1006664.e125.jpg" id="pcbi.1006664.e125g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M125"><mml:mrow><mml:mi>E</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mi>N</mml:mi></mml:msub><mml:mo>|</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&#x0003e;</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>N</mml:mi></mml:msub></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mtext>ln</mml:mtext><mml:mi>N</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mtext>ln</mml:mtext><mml:mi>i</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:math></alternatives></disp-formula>
then we can solve the first of these two equations for <inline-formula id="pcbi.1006664.e126"><alternatives><graphic xlink:href="pcbi.1006664.e126.jpg" id="pcbi.1006664.e126g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M126"><mml:mi>i</mml:mi></mml:math></alternatives></inline-formula>, assuming <inline-formula id="pcbi.1006664.e127"><alternatives><graphic xlink:href="pcbi.1006664.e127.jpg" id="pcbi.1006664.e127g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M127"><mml:mi>P</mml:mi><mml:mfenced close="]" open="[" separators="|"><mml:mrow><mml:msub><mml:mrow><mml:msub><mml:mrow><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:msub><mml:mo>&#x0003c;</mml:mo><mml:mi>T</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mn>0.7</mml:mn></mml:math></alternatives></inline-formula> to obtain
<disp-formula id="pcbi.1006664.e128"><alternatives><graphic xlink:href="pcbi.1006664.e128.jpg" id="pcbi.1006664.e128g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M128"><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mtext>log</mml:mtext></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mn>0.7</mml:mn><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mi>s</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mi>N</mml:mi></mml:msup></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></disp-formula>
and then substitute this into the second equation to obtain
<disp-formula id="pcbi.1006664.e129"><alternatives><graphic xlink:href="pcbi.1006664.e129.jpg" id="pcbi.1006664.e129g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M129"><mml:mrow><mml:mi>E</mml:mi><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mi>N</mml:mi></mml:msub><mml:mo>|</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>&#x0003e;</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>N</mml:mi></mml:msub></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mn>2</mml:mn><mml:mtext>ln</mml:mtext><mml:mi>N</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mrow><mml:mtext>lnln</mml:mtext></mml:mrow><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mn>0.7</mml:mn><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mi>s</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mi>N</mml:mi></mml:msup></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow><mml:mo>}</mml:mo></mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mtext>lnln</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mi>s</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>}</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:mi>s</mml:mi></mml:mrow></mml:math></alternatives></disp-formula></p><p>The latter has to be divided by the number of cell divisions per year (assumed to be equal to 90 as in Stiehl et al. [<xref rid="pcbi.1006664.ref045" ref-type="bibr">45</xref>]) to obtain time in years.</p><p>The resulting mutant cell counts and the expected age at fixation of the <italic>CSF3R</italic> truncation mutation are collected in the second and fourth column of <bold><xref rid="pcbi.1006664.t001" ref-type="table">Table 1</xref></bold>, respectively.</p><p>For <inline-formula id="pcbi.1006664.e130"><alternatives><graphic xlink:href="pcbi.1006664.e130.jpg" id="pcbi.1006664.e130g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M130"><mml:mi>s</mml:mi></mml:math></alternatives></inline-formula> from the interval (0.02, 0.1), the estimates of the expected time to fixation of the mutant (time when only mutant allele remains) belong to the interval [4.86, 23.41] (yr), and are approximately consistent with the timing of the sMDS onset. From the European SCN Registry data, age at diagnosis of SCN with sMDS and <italic>CSF3R</italic> mutation is 13 &#x000b1; 9 years. However, it is necessary that at the time G-CSF treatment begins, <inline-formula id="pcbi.1006664.e131"><alternatives><graphic xlink:href="pcbi.1006664.e131.jpg" id="pcbi.1006664.e131g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M131"><mml:mi>i</mml:mi></mml:math></alternatives></inline-formula> = 11&#x02013;60 mutant cells are already present in the cell population (second column of <bold><xref rid="pcbi.1006664.t001" ref-type="table">Table 1</xref></bold>).</p></sec><sec id="sec017"><title>Determination of the mutation rates required to obtain the mutant cell counts at birth</title><p>To shed light at the possibility of this number of mutants being present approximately at the birth time, we solved Equation (3) in the <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold> to obtain the estimates of mutation rate <inline-formula id="pcbi.1006664.e132"><alternatives><graphic xlink:href="pcbi.1006664.e132.jpg" id="pcbi.1006664.e132g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M132"><mml:mi>&#x003bc;</mml:mi></mml:math></alternatives></inline-formula> which makes it possible, absent selection by G-CSF, to obtain the corresponding initial mutant count <inline-formula id="pcbi.1006664.e133"><alternatives><graphic xlink:href="pcbi.1006664.e133.jpg" id="pcbi.1006664.e133g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M133"><mml:mi>i</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mi>i</mml:mi></mml:math></alternatives></inline-formula> in the range 11&#x02013;60 in the fetal hematopoietic population of HSC and CMP expanding to the size of about <inline-formula id="pcbi.1006664.e134"><alternatives><graphic xlink:href="pcbi.1006664.e134.jpg" id="pcbi.1006664.e134g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M134"><mml:mi>N</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:mi>N</mml:mi></mml:math></alternatives></inline-formula> = 1.98&#x000d7;10<sup>8</sup> cells/kg &#x000d7;5 kg (the approximate infant body weight).</p><p>Mathematically, under the branching process model (<bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold>), we obtain the equations for the expected (average) number <inline-formula id="pcbi.1006664.e135"><alternatives><graphic xlink:href="pcbi.1006664.e135.jpg" id="pcbi.1006664.e135g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M135"><mml:mi>N</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula> of normal and <inline-formula id="pcbi.1006664.e136"><alternatives><graphic xlink:href="pcbi.1006664.e136.jpg" id="pcbi.1006664.e136g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M136"><mml:mi>i</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced></mml:math></alternatives></inline-formula>of mutant cells [<xref rid="pcbi.1006664.ref008" ref-type="bibr">8</xref>]
<disp-formula id="pcbi.1006664.e137"><alternatives><graphic xlink:href="pcbi.1006664.e137.jpg" id="pcbi.1006664.e137g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M137"><mml:mrow><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mtext>exp</mml:mtext><mml:mo stretchy="false">[</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mi>&#x003bc;</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>&#x003bb;</mml:mi><mml:mi>t</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:mo>,</mml:mo><mml:mi>i</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>{</mml:mo><mml:mi>exp</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi>&#x003bb;</mml:mi><mml:mi>t</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mtext>exp</mml:mtext><mml:mo stretchy="false">[</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mi>&#x003bc;</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi>&#x003bb;</mml:mi><mml:mi>t</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:mo>}</mml:mo></mml:mrow></mml:math></alternatives></disp-formula></p><p>Eliminating time from the relationship between <inline-formula id="pcbi.1006664.e138"><alternatives><graphic xlink:href="pcbi.1006664.e138.jpg" id="pcbi.1006664.e138g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M138"><mml:mi>N</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula> and <inline-formula id="pcbi.1006664.e139"><alternatives><graphic xlink:href="pcbi.1006664.e139.jpg" id="pcbi.1006664.e139g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M139"><mml:mi>i</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced></mml:math></alternatives></inline-formula>, we obtain that the expected number of mutant cells is equal to
<disp-formula id="pcbi.1006664.e140"><alternatives><graphic xlink:href="pcbi.1006664.e140.jpg" id="pcbi.1006664.e140g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M140"><mml:mrow><mml:mi>i</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x02212;</mml:mo><mml:msubsup><mml:mi>N</mml:mi><mml:mn>0</mml:mn><mml:mi>&#x003bc;</mml:mi></mml:msubsup><mml:mi>N</mml:mi><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mi>&#x003bc;</mml:mi></mml:mrow></mml:msup><mml:mspace width="0.25em"/><mml:mo>&#x02245;</mml:mo><mml:mspace width="0.25em"/><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mi>N</mml:mi><mml:msup><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mi>&#x003bc;</mml:mi></mml:mrow></mml:msup><mml:mspace width="0.25em"/><mml:mo>&#x02245;</mml:mo><mml:mspace width="0.25em"/><mml:mi>&#x003bc;</mml:mi><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mtext>ln</mml:mtext><mml:mspace width="0.25em"/><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives></disp-formula>
where <inline-formula id="pcbi.1006664.e141"><alternatives><graphic xlink:href="pcbi.1006664.e141.jpg" id="pcbi.1006664.e141g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M141"><mml:mi>N</mml:mi><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>)</mml:mo></mml:math></alternatives></inline-formula> (resp. <inline-formula id="pcbi.1006664.e142"><alternatives><graphic xlink:href="pcbi.1006664.e142.jpg" id="pcbi.1006664.e142g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M142"><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></alternatives></inline-formula>) is the number of cells after (resp. before) expansion. The approximation on the right-hand side is valid for moderate <inline-formula id="pcbi.1006664.e143"><alternatives><graphic xlink:href="pcbi.1006664.e143.jpg" id="pcbi.1006664.e143g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M143"><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:math></alternatives></inline-formula> and small <inline-formula id="pcbi.1006664.e144"><alternatives><graphic xlink:href="pcbi.1006664.e144.jpg" id="pcbi.1006664.e144g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M144"><mml:mi>&#x003bc;</mml:mi></mml:math></alternatives></inline-formula>. Inverting this expression, we obtain the mutation rates for a given expected number of mutant cells.</p><p>The resulting mutation rates per cell division, ranging from 9.57&#x000d7;10<sup>&#x02212;10</sup> to 4.99&#x000d7;10<sup>&#x02212;09</sup>, with cell cycle time of the CMP (which dominate in the pooled HSC and CMP population; see further on) assumed equal to 4 days (as in Stiehl et al. [<xref rid="pcbi.1006664.ref045" ref-type="bibr">45</xref>]), do not exceed the values considered normal for human cells (<bold><xref rid="pcbi.1006664.t001" ref-type="table">Table 1</xref></bold>).</p><p>As for <bold><xref rid="pcbi.1006664.t002" ref-type="table">Table 2</xref></bold>, we select the mutation rates and expected times to fixation to be a subset of those in <bold><xref rid="pcbi.1006664.t001" ref-type="table">Table 1</xref></bold>and compare the respective selection coefficients stemming from the simplified model and the comprehensive model. A more complete review of possible parameter combination is possible using <bold><xref ref-type="fig" rid="pcbi.1006664.g002">Fig 2</xref></bold>as a nomogram; see further on.</p><table-wrap id="pcbi.1006664.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pcbi.1006664.t002</object-id><label>Table 2</label><caption><title>Comparison of estimates of selection coefficients needed for fixation of the <italic>CSF3R mutant</italic>.</title></caption><alternatives><graphic id="pcbi.1006664.t002g" xlink:href="pcbi.1006664.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" style="border-bottom:thick" rowspan="1" colspan="1">Age at <italic>CSF3R</italic> truncation<break/>fixation (yr)</th><th align="left" style="border-bottom:thick" rowspan="1" colspan="1">Mutation rate <inline-formula id="pcbi.1006664.e145"><alternatives><graphic id="pcbi.1006664.e145g" xlink:href="pcbi.1006664.e145"/><mml:math id="M145"><mml:mi mathvariant="bold-italic">&#x003bc;</mml:mi></mml:math></alternatives></inline-formula><break/>(cell division<sup>-1</sup>)</th><th align="left" style="border-bottom:thick" rowspan="1" colspan="1">Selection coefficient (<inline-formula id="pcbi.1006664.e146"><alternatives><graphic id="pcbi.1006664.e146g" xlink:href="pcbi.1006664.e146"/><mml:math id="M146"><mml:mi mathvariant="bold-italic">s</mml:mi></mml:math></alternatives></inline-formula>), based on proof-of-principle model</th><th align="left" style="border-bottom:thick" rowspan="1" colspan="1">Selection coefficient (<inline-formula id="pcbi.1006664.e147"><alternatives><graphic id="pcbi.1006664.e147g" xlink:href="pcbi.1006664.e147"/><mml:math id="M147"><mml:mi mathvariant="bold-italic">s</mml:mi></mml:math></alternatives></inline-formula>), based on comprehensive model</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">1 &#x000d7; 10<sup>&#x02212;9</sup></td><td align="left" rowspan="1" colspan="1">0.10</td><td align="left" rowspan="1" colspan="1">0.054</td></tr><tr><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">2.5 &#x000d7; 10<sup>&#x02212;9</sup></td><td align="left" rowspan="1" colspan="1">0.04</td><td align="left" rowspan="1" colspan="1">0.014</td></tr><tr><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">5 &#x000d7; 10<sup>&#x02212;9</sup></td><td align="left" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">0.008</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>Comparison of estimates of selection coefficients (rounded) needed for fixation of the <italic>CSF3R</italic> truncation mutant at a given age, based on the proof-of-principle and comprehensive models, with the corresponding mutation rates (rounded) corresponding to simulations underlying estimates in <bold><xref rid="pcbi.1006664.t001" ref-type="table">Table 1</xref></bold>.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="sec018"><title>Comprehensive model of fixation of CSF3R truncation mutants</title><p>The results of the proof-of-principle modeling summarized in <bold><xref rid="pcbi.1006664.t001" ref-type="table">Table 1</xref></bold>suggest that it is feasible to build a more comprehensive model consistent with normal hematopoiesis as well as mutation and selection mechanisms modified by the age-dependent cellularity of the bone marrow and administration of pharmacological G-CSF.</p><sec id="sec019"><title>Estimates of the parameters of the model of age-dependent dynamics of the granulocyte arm of the hematopoietic system</title><p>We assume that the total number of HSC, CMP, and granulocytes is proportional to body weight, which increases according to Theron's formula [<xref rid="pcbi.1006664.ref049" ref-type="bibr">49</xref>] from 3.4 kg at the birth time to 75 kg in the adult life. The exact numbers of these cells at time <inline-formula id="pcbi.1006664.e148"><alternatives><graphic xlink:href="pcbi.1006664.e148.jpg" id="pcbi.1006664.e148g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M148"><mml:mi>t</mml:mi></mml:math></alternatives></inline-formula> are calculated based on the estimates given by Stiehl et al. [<xref rid="pcbi.1006664.ref045" ref-type="bibr">45</xref>] (in that paper&#x02019;s Online Supplement, Scenario 2). Further details are available in the corresponding section of the <bold><xref ref-type="supplementary-material" rid="pcbi.1006664.s001">S1 Appendix</xref></bold>. <bold><xref ref-type="fig" rid="pcbi.1006664.g006">Fig 6</xref></bold>presents the age-trajectories of model coefficients as well as those of the cell numbers in the two compartments and the flux rate of mature granulocytes into blood.</p></sec><sec id="sec020"><title>Mutation rate, selection and age at sMDS onset in the detailed model including recurrent mutation</title><p>The main results of the paper are obtained by application of the comprehensive model of expansion of the <italic>CSF3R</italic> truncation mutants in the bone marrow. As described in Methods section, the model hypotheses are consistent with the age-dependence of the cell number in the CMP compartment. We disregard the influx of mutants arising in the HSC compartment, since this is a relatively minor influence compared to their number in the CMP, the increase of which is driven by their selective advantage following the G-CSF treatment. Because the Moran model with recurrent mutation has mutant fixation probability equal to 1, it applies strictly speaking only to the 70% of cases with <italic>CSF3R</italic> truncation mutation fixed at the sMDS diagnosis.</p><p><bold><xref ref-type="fig" rid="pcbi.1006664.g002">Fig 2A</xref></bold> depicts the age at which the <italic>CSF3R</italic> truncation mutants replace the normal cells in the CMP compartment. The age at replacement reaches the mean value of 13 years observed in clinical data for a range of parameter values, including mutation rate expected for human genome (ca. 10<sup>&#x02212;9</sup>) and modest selection coefficient values such as 0.014 consistent with small selective advantage expected based on <bold><xref ref-type="fig" rid="pcbi.1006664.g003">Fig 3</xref></bold>though not explicitly quantifiable. <bold><xref ref-type="fig" rid="pcbi.1006664.g002">Fig 2B</xref></bold> depicts the values of the selection coefficient <inline-formula id="pcbi.1006664.e149"><alternatives><graphic xlink:href="pcbi.1006664.e149.jpg" id="pcbi.1006664.e149g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M149"><mml:mi>s</mml:mi></mml:math></alternatives></inline-formula>, which for a given mutation rate lead to sMDS onset at 4, 13 and 22 years, respectively.</p><p>Comparison of simulations in <bold><xref ref-type="fig" rid="pcbi.1006664.g002">Fig 2</xref></bold>(comprehensive model) and computations in <bold><xref rid="pcbi.1006664.t001" ref-type="table">Table 1</xref></bold>(simplified model), leads to the conclusions summarized in <bold><xref rid="pcbi.1006664.t002" ref-type="table">Table 2</xref></bold>. Estimates of the selection coefficients needed for fixation of the <italic>CSF3R</italic> truncation mutant at ages 4, 13 and 22 years obtained from the comprehensive model are about 2&#x02013;3 times higher than those based on the simplified model, with the corresponding mutation rates adjusted to those required in the simplified model. This difference stems from two facts: (1) the simplified model does not account for the change of the hematopoietic system performance with age, and (2) the comprehensive model includes recurrent mutations of <italic>CSF3R</italic> over the lifetime not only in the fetal period. In both models, the mutation rates and selection coefficients required seem to be within acceptable ranges.</p><p>Another graph, in <bold><xref ref-type="fig" rid="pcbi.1006664.g002">Fig 2C</xref></bold>, depicts the corresponding mutant count at 1 year of age. We see that at mutation rates ranging over 10<sup>&#x02212;9</sup>&#x02013;10<sup>&#x02212;7</sup>, the mutant count at birth remains in the 10<sup>1</sup>&#x02013;10<sup>3</sup> range. These results confirm the proof-of-concept analysis and show that in the range of &#x0201c;normal&#x0201d; human mutation rates, the number of mutants at birth is of the order of 10<sup>2</sup>&#x02014;practically undetectable even by very deep sequencing.</p></sec></sec></sec><sec sec-type="conclusions" id="sec021"><title>Discussion</title><p>Here we presented a model of fixation of a <italic>CSF3R</italic> truncation mutant in the transition from an inherited neutropenia to sMDS: from the expansion phase in the prenatal hematopoietic tissues, to initiation of the G-CSF treatment, to expansion of the mutant, and to replacement of the normal bone marrow by the pre-leukemic mutants. By modifying the simple Moran model of population genetics, we provided an explanation for the evolution of sMDS in about 70% of cases in which <italic>CSF3R</italic> truncation mutant acts as an oncogenic driver. We first used a proof-of-concept two-stage model including the initial creation of the mutant clone before the selective agent G-CSF has been applied, followed by the period of selective pressure after initiation of treatment. We followed up with a more comprehensive model, which used the estimates of age-dependent productivity changes in hematopoietic stem cells, obtained based on telomere shortening estimates by the Abkowitz and Aviv groups [<xref rid="pcbi.1006664.ref047" ref-type="bibr">47</xref>, <xref rid="pcbi.1006664.ref048" ref-type="bibr">48</xref>].</p><p>Our model provides a real-world setting that may further illuminate principles of clonal hematopoiesis of indeterminate potential, first described as age-related clonal hematopoiesis. As recently summarized by [<xref rid="pcbi.1006664.ref050" ref-type="bibr">50</xref>], HSC clonality and association with malignancy begins with somatic genetic lesions in adult stem cells that accumulate and persist and that &#x0201c;given a large enough population (of HSC), every base pair in the genome will be mutated within at least one HSC&#x0201d;. Further, &#x0201c;these mutations provide the substrate for clonal selection&#x0201d;. The original and distinctive feature of our present model is to show that mutations occurring during the bone marrow expansion in the fetal period are likely to play a major role in creating this substrate.</p><p>The expected times to fixation of the <italic>CSF3R</italic> truncation mutant (4&#x02013;22 years) are consistent with the timing of the sMDS onset. According to data published from the European SCN Registry data, the average age at diagnosis of SCN with sMDS and <italic>CSF3R</italic> mutation is 13 &#x000b1; 9 years [<xref rid="pcbi.1006664.ref051" ref-type="bibr">51</xref>]. The 70% fixation probability requires 11&#x02013;60 &#x0201c;initial&#x0201d; cells harboring the mutation. We experimentally validated our mathematical model by measuring the growth advantage of the CSF3R D715-expressing cells and found a significant growth advantage (<bold><xref ref-type="fig" rid="pcbi.1006664.g001">Fig 1A</xref></bold>). Further validation will require next generation sequencing of specimens from these rare patients. Qiu et al. [<xref rid="pcbi.1006664.ref052" ref-type="bibr">52</xref>] recently reported that this truncation mutation also permits granulocytic precursors to avoid apoptosis.</p><p>Our comprehensive model is based on the hypothesis that the rate of cell division after birth, when the rapid expansion of bone marrow slows down, is still very high. Hence, acquisition of new mutants during that phase is still substantial. However, selection is the force that leads the mutant-receptor cells to dominate. This also means that supply of new mutants in the expansion phase might not be necessary for the disease to emerge. However, it is likely that proliferation slows down by one or two orders of magnitude, depending on exact characteristics of subtypes of stem cells. Then in order to fit the data, somewhat higher selection coefficients are needed. In that case, the comprehensive model will behave approximately as the &#x0201c;proof of the concept&#x0201d; model, i.e. most of the mutant are supplied in the marrow expansion stage.</p><p>An alternative hypothesis states that an inherited neutropenia induces a maladaptive increase in replicative stress and higher mutation rate in HSC that contributes to transformation to sMDS/AML [<xref rid="pcbi.1006664.ref053" ref-type="bibr">53</xref>]. However, measurements of the mutation burden in individual hematopoietic stem/progenitor cells (HSPCs) from SCN patients failed to support that. CD34<sup>+</sup>CD38<sup>-</sup> cells were sorted from blood or bone marrow samples and cultured for 3&#x02013;4 weeks on irradiated stromal feeder cells. The exomes of the expanded HSPC clones were sequenced with unsorted hematopoietic cells from the same patient served as a normal control. The average number of somatic mutations per exome was 3.6 &#x000b1; 1.2 for SCN, compared to 3.9 &#x000b1; 0.4 for the healthy controls. Those patient-derived findings support our model. Our conclusions require that the mutation rate per site per cell division equals about 10<sup>&#x02212;9</sup>, which is consistent with normal mutation rate in human genome.</p><p>This latter issue warrants discussion since the somatic mutation rate in humans is about two orders of magnitude higher than the germline mutation rate, as suggested by [<xref rid="pcbi.1006664.ref054" ref-type="bibr">54</xref>]. However, a recent paper by Milholland et al. [<xref rid="pcbi.1006664.ref055" ref-type="bibr">55</xref>], argues that this former (somatic rate) is of the order of 10<sup>&#x02212;9</sup> per base per mitosis, while the former (germline rate) is of the order of 10<sup>&#x02212;11</sup> per base per mitosis (<bold><xref ref-type="fig" rid="pcbi.1006664.g001">Fig 1B</xref></bold> in that paper). Moreover, as seen in our <bold><xref ref-type="fig" rid="pcbi.1006664.g002">Fig 2</xref></bold>, using the 10<sup>&#x02212;7</sup> mutation rate [<xref rid="pcbi.1006664.ref054" ref-type="bibr">54</xref>] would only slightly change our conclusions.</p><p>Two other mechanisms drive the expansion of the CSF3R truncation mutants, (i) the initial CSF3R truncation mutant cell clones arising in the expansion phase of fetal hematopoietic bone marrow and (ii) competitive advantage of the CSF3R truncation mutant harboring cells at later ages, hypothetically due to increased G-CSF pressure. &#x0201c;Mutator phenotype&#x0201d; does not need to be invoked in the SCN progression to sMDS.</p><p>A characteristic feature of human cancers is their wide heterogeneity with respect to extent of involvement, genotype, and rate of progression and spread [<xref rid="pcbi.1006664.ref056" ref-type="bibr">56</xref>]. This variability contrasts markedly to induced animal tumors, which grow at a relatively uniform rate. sMDS/AML secondary to SCN is not an exception, with onset varying from 1 to 38 years of age. Previously, we constructed a stochastic model of the SNC&#x02192;sMDS&#x02192;sAML transition based on stochastic events [<xref rid="pcbi.1006664.ref009" ref-type="bibr">9</xref>]. It considered each new mutation to provide more selective advantage to the arising clone. This linear structure of mutation conferred desirable simplicity to modeling but was not necessarily realistic. In the framework of multitype branching processes and special processes such as Griffiths and Pakes branching infinite allele model [<xref rid="pcbi.1006664.ref057" ref-type="bibr">57</xref>, <xref rid="pcbi.1006664.ref058" ref-type="bibr">58</xref>], more complicated scenarios might be contemplated. Interestingly, the model of ref. [<xref rid="pcbi.1006664.ref009" ref-type="bibr">9</xref>] suggests that the spread in the age of onset of sAML is not due solely to stochastic nature of clone transitions, but requires a large variability in proliferative potential from one affected individual to another.</p><p>Similar effect can be predicted in the Moran process. According to [<xref rid="pcbi.1006664.ref038" ref-type="bibr">38</xref>], the time course of the Moran process under mutant selective advantage can be split into three periods: (1) relatively long period from small number of mutant cells to a threshold, followed by (2) a much shorter period from the threshold to near-fixation of the mutant, and (3) a relatively long period to complete fixation. Accordingly, once the mutant count exceeds certain threshold, the process accelerates. This results in the spread of times to fixation depending at least as strongly on the selection coefficient as on the &#x0201c;intrinsic&#x0201d; randomness. This justifies the approach we took in this study, to concentrate on the effects of the selection coefficient. In addition, determination of the threshold may help establish a target for monitoring the progress of the disease. Gaining more insight will require a further study.</p><p>While our model advances the understanding of multistep progression to cancer with a real-world condition and application to the clinic, other factors could be incorporated. These include: a correlation between G-CSF dosage for neutrophil recovery in SCN patients and the risk of malignant transformation and acquisition of an additional mutation, such as <italic>RUNX1</italic>, in the evolution to sAML.</p><p>In the current report, we focus on a single aspect of the SCN-related leukemogenesis: expansion of <italic>CSF3R</italic> truncation mutant cells leading to the sMDS transformation. The model we present here provides potentially testable hypotheses (i) the <italic>CSF3R</italic> truncation mutants are present in <inline-formula id="pcbi.1006664.e150"><alternatives><graphic xlink:href="pcbi.1006664.e150.jpg" id="pcbi.1006664.e150g" mimetype="image" position="anchor" orientation="portrait"/><mml:math id="M150"><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo>-</mml:mo><mml:msup><mml:mrow><mml:mn>10</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:math></alternatives></inline-formula> cells before G-CSF treatment is applied and (ii) a slight selective advantage of the <italic>CSF3R</italic> truncation mutant-harboring cells under G-CSF pressure is sufficient to lead to their expansion. The second hypothesis seems to be consistent with findings in ref [<xref rid="pcbi.1006664.ref053" ref-type="bibr">53</xref>]. Current dogma holds that clonal dynamics in relation to the development of sMDS/AML are highly heterogeneous and unpredictable. Our model supports the clinical value of more accurate disease surveillance with next generation sequencing and better timing of therapeutic interventions, such as stem cell transplantation.</p></sec><sec sec-type="supplementary-material" id="sec022"><title>Supporting information</title><supplementary-material content-type="local-data" id="pcbi.1006664.s001"><label>S1 Appendix</label><caption><title>Supporting methods.</title><p>(DOCX)</p></caption><media xlink:href="pcbi.1006664.s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pcbi.1006664.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>McFarland</surname><given-names>CD</given-names></name>, <name><surname>Mirny</surname><given-names>LA</given-names></name>, <name><surname>Korolev</surname><given-names>KS</given-names></name>. <article-title>Tug-of-war between driver and passenger mutations in cancer and other adaptive processes</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2014</year>;<volume>111</volume>(<issue>42</issue>):<fpage>15138</fpage>&#x02013;<lpage>43</lpage>. Epub 2014/10/04. <pub-id pub-id-type="doi">10.1073/pnas.1404341111</pub-id>
<?supplied-pmid 25277973?><pub-id pub-id-type="pmid">25277973</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>McFarland</surname><given-names>CD</given-names></name>, <name><surname>Yaglom</surname><given-names>JA</given-names></name>, <name><surname>Wojtkowiak</surname><given-names>JW</given-names></name>, <name><surname>Scott</surname><given-names>JG</given-names></name>, <name><surname>Morse</surname><given-names>DL</given-names></name>, <name><surname>Sherman</surname><given-names>MY</given-names></name>, <etal>et al</etal>
<article-title>The Damaging Effect of Passenger Mutations on Cancer Progression</article-title>. <source>Cancer Res</source>. <year>2017</year>;<volume>77</volume>(<issue>18</issue>):<fpage>4763</fpage>&#x02013;<lpage>72</lpage>. Epub 2017/05/26. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-3283-T</pub-id>
<?supplied-pmid 28536279?><pub-id pub-id-type="pmid">28536279</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Davis</surname><given-names>A</given-names></name>, <name><surname>Gao</surname><given-names>R</given-names></name>, <name><surname>Navin</surname><given-names>N</given-names></name>. <article-title>Tumor evolution: Linear, branching, neutral or punctuated?</article-title>
<source>Biochim Biophys Acta</source>. <year>2017</year>;<volume>1867</volume>(<issue>2</issue>):<fpage>151</fpage>&#x02013;<lpage>61</lpage>. Epub 2017/01/23. <pub-id pub-id-type="doi">10.1016/j.bbcan.2017.01.003</pub-id>
<?supplied-pmid 28110020?><pub-id pub-id-type="pmid">28110020</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Gao</surname><given-names>R</given-names></name>, <name><surname>Davis</surname><given-names>A</given-names></name>, <name><surname>McDonald</surname><given-names>TO</given-names></name>, <name><surname>Sei</surname><given-names>E</given-names></name>, <name><surname>Shi</surname><given-names>X</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Punctuated copy number evolution and clonal stasis in triple-negative breast cancer</article-title>. <source>Nat Genet</source>. <year>2016</year>;<volume>48</volume>(<issue>10</issue>):<fpage>1119</fpage>&#x02013;<lpage>30</lpage>. Epub 2016/08/16. <pub-id pub-id-type="doi">10.1038/ng.3641</pub-id>
<?supplied-pmid 27526321?><pub-id pub-id-type="pmid">27526321</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref005"><label>5</label><mixed-citation publication-type="book"><name><surname>Durrett</surname><given-names>R</given-names></name>. <source>Branching process models of cancer</source>. <name><surname>Golubitsky</surname><given-names>M</given-names></name>, <name><surname>Reed</surname><given-names>M.</given-names></name>, editor: <collab>Springer</collab>, <publisher-loc>Cham</publisher-loc>; <year>2015</year>
<fpage>63</fpage> p.</mixed-citation></ref><ref id="pcbi.1006664.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Tomasetti</surname><given-names>C</given-names></name>, <name><surname>Durrett</surname><given-names>R</given-names></name>, <name><surname>Kimmel</surname><given-names>M</given-names></name>, <name><surname>Lambert</surname><given-names>A</given-names></name>, <name><surname>Parmigiani</surname><given-names>G</given-names></name>, <name><surname>Zauber</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Role of stem-cell divisions in cancer risk</article-title>. <source>Nature</source>. <year>2017</year>;<volume>548</volume>(<issue>7666</issue>):<fpage>E13</fpage>&#x02013;<lpage>E4</lpage>. Epub 2017/08/11. <pub-id pub-id-type="doi">10.1038/nature23302</pub-id> .<?supplied-pmid 28796214?><pub-id pub-id-type="pmid">28796214</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref007"><label>7</label><mixed-citation publication-type="book"><name><surname>Nowak</surname><given-names>MA</given-names></name>. <chapter-title>Evolutionary dynamics</chapter-title>
<source>Exploring the Equations of Life</source>: <publisher-name>Harvard University Press</publisher-name>; <year>2006</year>.</mixed-citation></ref><ref id="pcbi.1006664.ref008"><label>8</label><mixed-citation publication-type="book"><name><surname>Kimmel</surname><given-names>M</given-names></name>, <name><surname>Axelrod</surname><given-names>DE</given-names></name>. <source>Branching Processes in Biology</source>: <publisher-name>Springer</publisher-name>
<year>2015</year>.</mixed-citation></ref><ref id="pcbi.1006664.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Kimmel</surname><given-names>M</given-names></name>, <name><surname>Corey</surname><given-names>S</given-names></name>. <article-title>Stochastic Hypothesis of Transition from Inborn Neutropenia to AML: Interactions of Cell Population Dynamics and Population Genetics</article-title>. <source>Frontiers in oncology</source>. <year>2013</year>;<volume>3</volume>:<fpage>89</fpage>
<pub-id pub-id-type="doi">10.3389/fonc.2013.00089</pub-id>
<?supplied-pmid 23641360?><pub-id pub-id-type="pmid">23641360</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Whichard</surname><given-names>ZL</given-names></name>, <name><surname>Sarkar</surname><given-names>CA</given-names></name>, <name><surname>Kimmel</surname><given-names>M</given-names></name>, <name><surname>Corey</surname><given-names>SJ</given-names></name>. <article-title>Hematopoiesis and its disorders: a systems biology approach</article-title>. <source>Blood</source>. <year>2010</year>;<volume>115</volume>(<issue>12</issue>):<fpage>2339</fpage>&#x02013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2009-08-215798</pub-id>
<?supplied-pmid 20103779?><pub-id pub-id-type="pmid">20103779</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Matatall</surname><given-names>KA</given-names></name>, <name><surname>Jeong</surname><given-names>M</given-names></name>, <name><surname>Chen</surname><given-names>S</given-names></name>, <name><surname>Sun</surname><given-names>D</given-names></name>, <name><surname>Chen</surname><given-names>F</given-names></name>, <name><surname>Mo</surname><given-names>Q</given-names></name>, <etal>et al</etal>
<article-title>Chronic Infection Depletes Hematopoietic Stem Cells through Stress-Induced Terminal Differentiation</article-title>. <source>Cell Rep</source>. <year>2016</year>;<volume>17</volume>(<issue>10</issue>):<fpage>2584</fpage>&#x02013;<lpage>95</lpage>. Epub 2016/12/08. <pub-id pub-id-type="doi">10.1016/j.celrep.2016.11.031</pub-id>
<?supplied-pmid 27926863?><pub-id pub-id-type="pmid">27926863</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Tomasetti</surname><given-names>C</given-names></name>, <name><surname>Vogelstein</surname><given-names>B</given-names></name>, <name><surname>Parmigiani</surname><given-names>G</given-names></name>. <article-title>Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2013</year>;<volume>110</volume>(<issue>6</issue>):<fpage>1999</fpage>&#x02013;<lpage>2004</lpage>. Epub 2013/01/25. <pub-id pub-id-type="doi">10.1073/pnas.1221068110</pub-id>
<?supplied-pmid 23345422?><pub-id pub-id-type="pmid">23345422</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Horwitz</surname><given-names>MS</given-names></name>, <name><surname>Corey</surname><given-names>SJ</given-names></name>, <name><surname>Grimes</surname><given-names>HL</given-names></name>, <name><surname>Tidwell</surname><given-names>T</given-names></name>. <article-title>ELANE mutations in cyclic and severe congenital neutropenia: genetics and pathophysiology</article-title>. <source>Hematology/oncology clinics of North America</source>. <year>2013</year>;<volume>27</volume>(<issue>1</issue>):<fpage>19</fpage>&#x02013;<lpage>41</lpage>, vii. <pub-id pub-id-type="doi">10.1016/j.hoc.2012.10.004</pub-id>
<?supplied-pmid 23351986?><pub-id pub-id-type="pmid">23351986</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Mehta</surname><given-names>HM</given-names></name>, <name><surname>Malandra</surname><given-names>M</given-names></name>, <name><surname>Corey</surname><given-names>SJ</given-names></name>. <article-title>G-CSF and GM-CSF in Neutropenia</article-title>. <source>J Immunol</source>. <year>2015</year>;<volume>195</volume>(<issue>4</issue>):<fpage>1341</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1500861</pub-id> .<?supplied-pmid 26254266?><pub-id pub-id-type="pmid">26254266</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Donadieu</surname><given-names>J</given-names></name>, <name><surname>Leblanc</surname><given-names>T</given-names></name>, <name><surname>Bader Meunier</surname><given-names>B</given-names></name>, <name><surname>Barkaoui</surname><given-names>M</given-names></name>, <name><surname>Fenneteau</surname><given-names>O</given-names></name>, <name><surname>Bertrand</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group</article-title>. <source>Haematologica</source>. <year>2005</year>;<volume>90</volume>(<issue>1</issue>):<fpage>45</fpage>&#x02013;<lpage>53</lpage>. Epub 2005/01/12. .<?supplied-pmid 15642668?><pub-id pub-id-type="pmid">15642668</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Rosenberg</surname><given-names>PS</given-names></name>, <name><surname>Alter</surname><given-names>BP</given-names></name>, <name><surname>Bolyard</surname><given-names>AA</given-names></name>, <name><surname>Bonilla</surname><given-names>MA</given-names></name>, <name><surname>Boxer</surname><given-names>LA</given-names></name>, <name><surname>Cham</surname><given-names>B</given-names></name>, <etal>et al</etal>
<article-title>The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy</article-title>. <source>Blood</source>. <year>2006</year>;<volume>107</volume>(<issue>12</issue>):<fpage>4628</fpage>&#x02013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2005-11-4370</pub-id>
<?supplied-pmid 16497969?><pub-id pub-id-type="pmid">16497969</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Kojima</surname><given-names>S</given-names></name>, <name><surname>Tsuchida</surname><given-names>M</given-names></name>, <name><surname>Matsuyama</surname><given-names>T</given-names></name>. <article-title>Myelodysplasia and leukemia after treatment of aplastic anemia with G-CSF</article-title>. <source>N Engl J Med</source>. <year>1992</year>;<volume>326</volume>(<issue>19</issue>):<fpage>1294</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM199205073261917</pub-id> .<?supplied-pmid 1373226?><pub-id pub-id-type="pmid">1373226</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Hershman</surname><given-names>D</given-names></name>, <name><surname>Neugut</surname><given-names>AI</given-names></name>, <name><surname>Jacobson</surname><given-names>JS</given-names></name>, <name><surname>Wang</surname><given-names>J</given-names></name>, <name><surname>Tsai</surname><given-names>WY</given-names></name>, <name><surname>McBride</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy</article-title>. <source>J Natl Cancer Inst</source>. <year>2007</year>;<volume>99</volume>(<issue>3</issue>):<fpage>196</fpage>&#x02013;<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/djk028</pub-id> .<?supplied-pmid 17284714?><pub-id pub-id-type="pmid">17284714</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Beekman</surname><given-names>R</given-names></name>, <name><surname>Touw</surname><given-names>IP</given-names></name>. <article-title>G-CSF and its receptor in myeloid malignancy</article-title>. <source>Blood</source>. <year>2010</year>;<volume>115</volume>(<issue>25</issue>):<fpage>5131</fpage>&#x02013;<lpage>6</lpage>. Epub 2010/03/20. <pub-id pub-id-type="doi">10.1182/blood-2010-01-234120</pub-id> .<?supplied-pmid 20237318?><pub-id pub-id-type="pmid">20237318</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Ehlers</surname><given-names>S</given-names></name>, <name><surname>Herbst</surname><given-names>C</given-names></name>, <name><surname>Zimmermann</surname><given-names>M</given-names></name>, <name><surname>Scharn</surname><given-names>N</given-names></name>, <name><surname>Germeshausen</surname><given-names>M</given-names></name>, <name><surname>von Neuhoff</surname><given-names>N</given-names></name>, <etal>et al</etal>
<article-title>Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse</article-title>. <source>Journal of clinical oncology: official journal of the American Society of Clinical Oncology</source>. <year>2010</year>;<volume>28</volume>(<issue>15</issue>):<fpage>2591</fpage>&#x02013;<lpage>7</lpage>. Epub 2010/04/22. <pub-id pub-id-type="doi">10.1200/JCO.2009.25.9010</pub-id> .<?supplied-pmid 20406937?><pub-id pub-id-type="pmid">20406937</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Touw</surname><given-names>IP</given-names></name>, <name><surname>Beekman</surname><given-names>R</given-names></name>. <article-title>Severe congenital neutropenia and chronic neutrophilic leukemia: an intriguing molecular connection unveiled by oncogenic mutations in CSF3R</article-title>. <source>Haematologica</source>. <year>2013</year>;<volume>98</volume>(<issue>10</issue>):<fpage>1490</fpage>&#x02013;<lpage>2</lpage>. Epub 2013/10/05. <pub-id pub-id-type="doi">10.3324/haematol.2013.090571</pub-id>
<?supplied-pmid 24091926?><pub-id pub-id-type="pmid">24091926</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Dong</surname><given-names>F</given-names></name>, <name><surname>Brynes</surname><given-names>RK</given-names></name>, <name><surname>Tidow</surname><given-names>N</given-names></name>, <name><surname>Welte</surname><given-names>K</given-names></name>, <name><surname>Lowenberg</surname><given-names>B</given-names></name>, <name><surname>Touw</surname><given-names>IP</given-names></name>. <article-title>Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia</article-title>. <source>N Engl J Med</source>. <year>1995</year>;<volume>333</volume>(<issue>8</issue>):<fpage>487</fpage>&#x02013;<lpage>93</lpage>. Epub 1995/08/24. <pub-id pub-id-type="doi">10.1056/NEJM199508243330804</pub-id> .<?supplied-pmid 7542747?><pub-id pub-id-type="pmid">7542747</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Germeshausen</surname><given-names>M</given-names></name>, <name><surname>Skokowa</surname><given-names>J</given-names></name>, <name><surname>Ballmaier</surname><given-names>M</given-names></name>, <name><surname>Zeidler</surname><given-names>C</given-names></name>, <name><surname>Welte</surname><given-names>K</given-names></name>. <article-title>G-CSF receptor mutations in patients with congenital neutropenia</article-title>. <source>Curr Opin Hematol</source>. <year>2008</year>;<volume>15</volume>(<issue>4</issue>):<fpage>332</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1097/MOH.0b013e328303b9f6</pub-id> .<?supplied-pmid 18536571?><pub-id pub-id-type="pmid">18536571</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Beekman</surname><given-names>R</given-names></name>, <name><surname>Valkhof</surname><given-names>MG</given-names></name>, <name><surname>Sanders</surname><given-names>MA</given-names></name>, <name><surname>van Strien</surname><given-names>PMH</given-names></name>, <name><surname>Haanstra</surname><given-names>JR</given-names></name>, <name><surname>Broeders</surname><given-names>L</given-names></name>, <etal>et al</etal>
<source>Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia</source><year>2012</year> 2012-05-31 00:00:00. <fpage>5071</fpage>&#x02013;<lpage>7</lpage> p.</mixed-citation></ref><ref id="pcbi.1006664.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Vogelstein</surname><given-names>B</given-names></name>, <name><surname>Fearon</surname><given-names>ER</given-names></name>, <name><surname>Hamilton</surname><given-names>SR</given-names></name>, <name><surname>Kern</surname><given-names>SE</given-names></name>, <name><surname>Preisinger</surname><given-names>AC</given-names></name>, <name><surname>Leppert</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Genetic alterations during colorectal-tumor development</article-title>. <source>N Engl J Med</source>. <year>1988</year>;<volume>319</volume>(<issue>9</issue>):<fpage>525</fpage>&#x02013;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM198809013190901</pub-id> .<?supplied-pmid 2841597?><pub-id pub-id-type="pmid">2841597</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Yates</surname><given-names>LR</given-names></name>, <name><surname>Campbell</surname><given-names>PJ</given-names></name>. <article-title>Evolution of the cancer genome</article-title>. <source>Nat Rev Genet</source>. <year>2012</year>;<volume>13</volume>(<issue>11</issue>):<fpage>795</fpage>&#x02013;<lpage>806</lpage>. <pub-id pub-id-type="doi">10.1038/nrg3317</pub-id>
<?supplied-pmid 23044827?><pub-id pub-id-type="pmid">23044827</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Ortmann</surname><given-names>CA</given-names></name>, <name><surname>Kent</surname><given-names>DG</given-names></name>, <name><surname>Nangalia</surname><given-names>J</given-names></name>, <name><surname>Silber</surname><given-names>Y</given-names></name>, <name><surname>Wedge</surname><given-names>DC</given-names></name>, <name><surname>Grinfeld</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Effect of mutation order on myeloproliferative neoplasms</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>372</volume>(<issue>7</issue>):<fpage>601</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1412098</pub-id> .<?supplied-pmid 25671252?><pub-id pub-id-type="pmid">25671252</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Martincorena</surname><given-names>I</given-names></name>, <name><surname>Roshan</surname><given-names>A</given-names></name>, <name><surname>Gerstung</surname><given-names>M</given-names></name>, <name><surname>Ellis</surname><given-names>P</given-names></name>, <name><surname>Van Loo</surname><given-names>P</given-names></name>, <name><surname>McLaren</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin</article-title>. <source>Science</source>. <year>2015</year>;<volume>348</volume>(<issue>6237</issue>):<fpage>880</fpage>&#x02013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1126/science.aaa6806</pub-id>
<?supplied-pmid 25999502?><pub-id pub-id-type="pmid">25999502</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>McCulloch</surname><given-names>EA</given-names></name>, <name><surname>Till</surname><given-names>JE</given-names></name>. <article-title>The radiation sensitivity of normal mouse bone marrow cells, determined by quantitative marrow transplantation into irradiated mice</article-title>. <source>Radiation research</source>. <year>1960</year>;<volume>13</volume>:<fpage>115</fpage>&#x02013;<lpage>25</lpage>. .<?supplied-pmid 13858509?><pub-id pub-id-type="pmid">13858509</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Groopman</surname><given-names>JE</given-names></name>, <name><surname>Molina</surname><given-names>JM</given-names></name>, <name><surname>Scadden</surname><given-names>DT</given-names></name>. <article-title>Hematopoietic growth factors. Biology and clinical applications</article-title>. <source>N Engl J Med</source>. <year>1989</year>;<volume>321</volume>(<issue>21</issue>):<fpage>1449</fpage>&#x02013;<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM198911233212106</pub-id> .<?supplied-pmid 2682244?><pub-id pub-id-type="pmid">2682244</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Kaushansky</surname><given-names>K</given-names></name>. <article-title>Lineage-specific hematopoietic growth factors</article-title>. <source>N Engl J Med</source>. <year>2006</year>;<volume>354</volume>(<issue>19</issue>):<fpage>2034</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra052706</pub-id> .<?supplied-pmid 16687716?><pub-id pub-id-type="pmid">16687716</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Rieger</surname><given-names>MA</given-names></name>, <name><surname>Hoppe</surname><given-names>PS</given-names></name>, <name><surname>Smejkal</surname><given-names>BM</given-names></name>, <name><surname>Eitelhuber</surname><given-names>AC</given-names></name>, <name><surname>Schroeder</surname><given-names>T</given-names></name>. <article-title>Hematopoietic cytokines can instruct lineage choice</article-title>. <source>Science</source>. <year>2009</year>;<volume>325</volume>(<issue>5937</issue>):<fpage>217</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1126/science.1171461</pub-id> .<?supplied-pmid 19590005?><pub-id pub-id-type="pmid">19590005</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref033"><label>33</label><mixed-citation publication-type="other">FlowJo L. FlowJo, LLC, 2013&#x02013;2018; [cited 2018]. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.flowjo.com/solutions/flowjo">https://www.flowjo.com/solutions/flowjo</ext-link>.</mixed-citation></ref><ref id="pcbi.1006664.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Kimmel</surname><given-names>M</given-names></name>. <article-title>Cellular population dynamics. I. Model construction and reformulation</article-title>. <source>Mathematical Biosciences</source>. <year>1980</year>;<volume>48</volume>(<issue>3/4</issue>):<fpage>211</fpage>&#x02013;<lpage>24</lpage>.</mixed-citation></ref><ref id="pcbi.1006664.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Kimmel</surname><given-names>M</given-names></name>. <article-title>Cellular population dynamics. II. Investigation of solutions</article-title>. <source>Mathematical Biosciences</source>. <year>1980</year>;<volume>48</volume>(<issue>3/4</issue>):<fpage>225</fpage>&#x02013;<lpage>39</lpage>.</mixed-citation></ref><ref id="pcbi.1006664.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Stute</surname><given-names>N</given-names></name>, <name><surname>Santana</surname><given-names>VM</given-names></name>, <name><surname>Rodman</surname><given-names>JH</given-names></name>, <name><surname>Schell</surname><given-names>MJ</given-names></name>, <name><surname>Ihle</surname><given-names>JN</given-names></name>, <name><surname>Evans</surname><given-names>WE</given-names></name>. <article-title>Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children</article-title>. <source>Blood</source>. <year>1992</year>;<volume>79</volume>(<issue>11</issue>):<fpage>2849</fpage>&#x02013;<lpage>54</lpage>. Epub 1992/06/01. .<?supplied-pmid 1375115?><pub-id pub-id-type="pmid">1375115</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref037"><label>37</label><mixed-citation publication-type="book"><name><surname>Alon</surname><given-names>U</given-names></name>. <source>An Introduction to Systems Biology: Design Principles of Biological Circuits</source>
<publisher-loc>Boca Raton, FL</publisher-loc>: <publisher-name>Chapman &#x00026; Hall</publisher-name>; <year>2007</year>.</mixed-citation></ref><ref id="pcbi.1006664.ref038"><label>38</label><mixed-citation publication-type="book"><name><surname>Durrett</surname><given-names>R</given-names></name>. <source>Probability Models for DNA Sequence Evolution</source>: <publisher-name>Springer</publisher-name>; <year>2008</year>.</mixed-citation></ref><ref id="pcbi.1006664.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Donadieu</surname><given-names>J</given-names></name>, <name><surname>Beaupain</surname><given-names>B</given-names></name>, <name><surname>Rety-Jacob</surname><given-names>F</given-names></name>, <name><surname>Nove-Josserand</surname><given-names>R</given-names></name>. <article-title>Respiratory distress and sudden death of a patient with GSDIb chronic neutropenia: possible role of pegfilgrastim</article-title>. <source>Haematologica</source>. <year>2009</year>;<volume>94</volume>(<issue>8</issue>):<fpage>1175</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.3324/haematol.2008.005330</pub-id>
<?supplied-pmid 19644144?><pub-id pub-id-type="pmid">19644144</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Dong</surname><given-names>F</given-names></name>, <name><surname>van Buitenen</surname><given-names>C</given-names></name>, <name><surname>Pouwels</surname><given-names>K</given-names></name>, <name><surname>Hoefsloot</surname><given-names>LH</given-names></name>, <name><surname>Lowenberg</surname><given-names>B</given-names></name>, <name><surname>Touw</surname><given-names>IP</given-names></name>. <article-title>Distinct cytoplasmic regions of the human granulocyte colony-stimulating factor receptor involved in induction of proliferation and maturation</article-title>. <source>Mol Cell Biol</source>. <year>1993</year>;<volume>13</volume>(<issue>12</issue>):<fpage>7774</fpage>&#x02013;<lpage>81</lpage>. Epub 1993/12/01. <?supplied-pmid 8246993?><pub-id pub-id-type="pmid">8246993</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Dowling</surname><given-names>DJ</given-names></name>, <name><surname>Levy</surname><given-names>O</given-names></name>. <article-title>Ontogeny of early life immunity</article-title>. <source>Trends Immunol</source>. <year>2014</year>;<volume>35</volume>(<issue>7</issue>):<fpage>299</fpage>&#x02013;<lpage>310</lpage>. Epub 2014/06/02. <pub-id pub-id-type="doi">10.1016/j.it.2014.04.007</pub-id>
<?supplied-pmid 24880460?><pub-id pub-id-type="pmid">24880460</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Orkin</surname><given-names>SH</given-names></name>, <name><surname>Zon</surname><given-names>LI</given-names></name>. <article-title>Hematopoiesis: an evolving paradigm for stem cell biology</article-title>. <source>Cell</source>. <year>2008</year>;<volume>132</volume>(<issue>4</issue>):<fpage>631</fpage>&#x02013;<lpage>44</lpage>. Epub 2008/02/26. <pub-id pub-id-type="doi">10.1016/j.cell.2008.01.025</pub-id>
<?supplied-pmid 18295580?><pub-id pub-id-type="pmid">18295580</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Goldie</surname><given-names>JH</given-names></name>, <name><surname>Coldman</surname><given-names>AJ</given-names></name>. <article-title>A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate</article-title>. <source>Cancer Treat Rep</source>. <year>1979</year>;<volume>63</volume>(<issue>11&#x02013;12</issue>):<fpage>1727</fpage>&#x02013;<lpage>33</lpage>. .<?supplied-pmid 526911?><pub-id pub-id-type="pmid">526911</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Goldie</surname><given-names>JH</given-names></name>, <name><surname>Coldman</surname><given-names>AJ</given-names></name>. <article-title>Genetic instability in the development of drug resistance</article-title>. <source>Semin Oncol</source>. <year>1985</year>;<volume>12</volume>(<issue>3</issue>):<fpage>222</fpage>&#x02013;<lpage>30</lpage>. .<?supplied-pmid 4048965?><pub-id pub-id-type="pmid">4048965</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Stiehl</surname><given-names>T</given-names></name>, <name><surname>Ho</surname><given-names>AD</given-names></name>, <name><surname>Marciniak-Czochra</surname><given-names>A</given-names></name>. <article-title>The impact of CD34+ cell dose on engraftment after SCTs: personalized estimates based on mathematical modeling</article-title>. <source>Bone Marrow Transplant</source>. <year>2014</year>;<volume>49</volume>(<issue>1</issue>):<fpage>30</fpage>&#x02013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/bmt.2013.138</pub-id> .<?supplied-pmid 24056742?><pub-id pub-id-type="pmid">24056742</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Arino</surname><given-names>O</given-names></name>, <name><surname>Kimmel</surname><given-names>M</given-names></name>. <article-title>Stability Analysis of Models of Cell Production Systems</article-title>. <source>Math Modelling</source>. <year>1986</year>;<volume>7</volume>(<issue>9&#x02013;12</issue>):<fpage>1269</fpage>&#x02013;<lpage>300</lpage>. <pub-id pub-id-type="doi">10.1016/0270-0255(86)90081-3</pub-id> PubMed PMID: WOS:A1986F488000009.</mixed-citation></ref><ref id="pcbi.1006664.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Shepherd</surname><given-names>BE</given-names></name>, <name><surname>Guttorp</surname><given-names>P</given-names></name>, <name><surname>Lansdorp</surname><given-names>PM</given-names></name>, <name><surname>Abkowitz</surname><given-names>JL</given-names></name>. <article-title>Estimating human hematopoietic stem cell kinetics using granulocyte telomere lengths</article-title>. <source>Exp Hematol</source>. <year>2004</year>;<volume>32</volume>(<issue>11</issue>):<fpage>1040</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.exphem.2004.07.023</pub-id> .<?supplied-pmid 15539081?><pub-id pub-id-type="pmid">15539081</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Sidorov</surname><given-names>I</given-names></name>, <name><surname>Kimura</surname><given-names>M</given-names></name>, <name><surname>Yashin</surname><given-names>A</given-names></name>, <name><surname>Aviv</surname><given-names>A</given-names></name>. <article-title>Leukocyte telomere dynamics and human hematopoietic stem cell kinetics during somatic growth</article-title>. <source>Exp Hematol</source>. <year>2009</year>;<volume>37</volume>(<issue>4</issue>):<fpage>514</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/j.exphem.2008.11.009</pub-id> .<?supplied-pmid 19216021?><pub-id pub-id-type="pmid">19216021</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>So</surname><given-names>TY</given-names></name>, <name><surname>Farrington</surname><given-names>E</given-names></name>, <name><surname>Absher</surname><given-names>RK</given-names></name>. <article-title>Evaluation of the accuracy of different methods used to estimate weights in the pediatric population</article-title>. <source>Pediatrics</source>. <year>2009</year>;<volume>123</volume>(<issue>6</issue>):<fpage>e1045</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1542/peds.2008-1968</pub-id> .<?supplied-pmid 19482737?><pub-id pub-id-type="pmid">19482737</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Jan</surname><given-names>M</given-names></name>, <name><surname>Ebert</surname><given-names>BL</given-names></name>, <name><surname>Jaiswal</surname><given-names>S</given-names></name>. <article-title>Clonal hematopoiesis</article-title>. <source>Semin Hematol</source>. <year>2017</year>;<volume>54</volume>(<issue>1</issue>):<fpage>43</fpage>&#x02013;<lpage>50</lpage>. Epub 2017/01/17. <pub-id pub-id-type="doi">10.1053/j.seminhematol.2016.10.002</pub-id> .<?supplied-pmid 28088988?><pub-id pub-id-type="pmid">28088988</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Skokowa</surname><given-names>J</given-names></name>, <name><surname>Steinemann</surname><given-names>D</given-names></name>, <name><surname>Katsman-Kuipers</surname><given-names>JE</given-names></name>, <name><surname>Zeidler</surname><given-names>C</given-names></name>, <name><surname>Klimenkova</surname><given-names>O</given-names></name>, <name><surname>Klimiankou</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Cooperativity of RUNX1 and CSF3R mutations in the development of leukemia in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis</article-title>. <source>Blood</source>. <year>2014</year> Epub 2014/02/14. <pub-id pub-id-type="doi">10.1182/blood-2013-11-538025</pub-id> .<?supplied-pmid 24523240?><pub-id pub-id-type="pmid">24523240</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Qiu</surname><given-names>Y</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Hu</surname><given-names>N</given-names></name>, <name><surname>Dong</surname><given-names>F</given-names></name>. A <article-title>Truncated Granulocyte Colony-stimulating Factor Receptor (G-CSFR) Inhibits Apoptosis Induced by Neutrophil Elastase G185R Mutant: implication for understanding CSF3R gene mutatiopns in severe congenital neutropenia</article-title>. <source>J Biol Chem</source>. <year>2017</year>;<volume>292</volume>(<issue>8</issue>):<fpage>3496</fpage>&#x02013;<lpage>505</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M116.755157</pub-id>
<?supplied-pmid 28073911?><pub-id pub-id-type="pmid">28073911</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Xia</surname><given-names>J</given-names></name>, <name><surname>Miller</surname><given-names>CA</given-names></name>, <name><surname>Baty</surname><given-names>J</given-names></name>, <name><surname>Ramesh</surname><given-names>A</given-names></name>, <name><surname>Jotte</surname><given-names>MRM</given-names></name>, <name><surname>Fulton</surname><given-names>RS</given-names></name>, <etal>et al</etal>
<article-title>Somatic mutations and clonal hematopoiesis in congenital neutropenia</article-title>. <source>Blood</source>. <year>2017</year>
<pub-id pub-id-type="doi">10.1182/blood-2017-08-801985</pub-id> .<?supplied-pmid 29092827?><pub-id pub-id-type="pmid">29092827</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Araten</surname><given-names>DJ</given-names></name>, <name><surname>Golde</surname><given-names>DW</given-names></name>, <name><surname>Zhang</surname><given-names>RH</given-names></name>, <name><surname>Thaler</surname><given-names>HT</given-names></name>, <name><surname>Gargiulo</surname><given-names>L</given-names></name>, <name><surname>Notaro</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>A quantitative measurement of the human somatic mutation rate</article-title>. <source>Cancer Res</source>. <year>2005</year>;<volume>65</volume>(<issue>18</issue>):<fpage>8111</fpage>&#x02013;<lpage>7</lpage>. Epub 2005/09/17. <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-1198</pub-id> .<?supplied-pmid 16166284?><pub-id pub-id-type="pmid">16166284</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Milholland</surname><given-names>B</given-names></name>, <name><surname>Dong</surname><given-names>X</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Hao</surname><given-names>X</given-names></name>, <name><surname>Suh</surname><given-names>Y</given-names></name>, <name><surname>Vijg</surname><given-names>J</given-names></name>. <article-title>Differences between germline and somatic mutation rates in humans and mice</article-title>. <source>Nat Commun</source>. <year>2017</year>;<volume>8</volume>:<fpage>15183</fpage> Epub 2017/05/10. <pub-id pub-id-type="doi">10.1038/ncomms15183</pub-id>
<?supplied-pmid 28485371?><pub-id pub-id-type="pmid">28485371</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Hanahan</surname><given-names>D</given-names></name>, <name><surname>Weinberg</surname><given-names>RA</given-names></name>. <article-title>Hallmarks of cancer: the next generation</article-title>. <source>Cell</source>. <year>2011</year>;<volume>144</volume>(<issue>5</issue>):<fpage>646</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id> .<?supplied-pmid 21376230?><pub-id pub-id-type="pmid">21376230</pub-id></mixed-citation></ref><ref id="pcbi.1006664.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Griffiths</surname><given-names>RC</given-names></name>, <name><surname>Pakes</surname><given-names>AG</given-names></name>. <article-title>An infinite alleles version of the simple branching process</article-title>. <source>Adv Appl Prob</source>. <year>1988</year>;<volume>20</volume>:<fpage>489</fpage>&#x02013;<lpage>524</lpage>.</mixed-citation></ref><ref id="pcbi.1006664.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>McDonald</surname><given-names>T</given-names></name>, <name><surname>Kimmel</surname><given-names>M</given-names></name>. <article-title>A multitype infinite-allele branching process with applications to cancer evolution</article-title>. <source>Journal of Applied Probability</source>
<year>2015</year>;<volume>52</volume>(<issue>3</issue>):<fpage>864</fpage>&#x02013;<lpage>76</lpage>.</mixed-citation></ref></ref-list></back></article>